US20220259617A1 - Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells - Google Patents

Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells Download PDF

Info

Publication number
US20220259617A1
US20220259617A1 US17/617,490 US202017617490A US2022259617A1 US 20220259617 A1 US20220259617 A1 US 20220259617A1 US 202017617490 A US202017617490 A US 202017617490A US 2022259617 A1 US2022259617 A1 US 2022259617A1
Authority
US
United States
Prior art keywords
cargo
protein
hevlp
gag
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/617,490
Other languages
English (en)
Inventor
J. Keith Joung
Peter Cabeceiras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Harvard University
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Priority to US17/617,490 priority Critical patent/US20220259617A1/en
Assigned to THE GENERAL HOSPITAL CORPORATION reassignment THE GENERAL HOSPITAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CABECEIRAS, Peter, JOUNG, J. KEITH
Publication of US20220259617A1 publication Critical patent/US20220259617A1/en
Assigned to THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE reassignment THE GENERAL HOSPITAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THE GENERAL HOSPITAL CORPORATION
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10051—Methods of production or purification of viral material
    • C12N2740/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Definitions

  • heVLPs engineered human-endogenous virus-like particles comprising a membrane comprising a phospholipid bilayer on the external side; and a cargo, e.g., a biomolecule and/or chemical cargo, disposed in the core of the heVLP on the inside of the membrane, wherein the heVLP does not comprise a protein from non-human gag or pol, and methods of use thereof for delivery of the cargo to cells.
  • heVLPs that are capable of packaging and delivering DNA, RNA, protein, chemical compounds and/or molecules, and any combination of these four entities into eukaryotic cells.
  • the non-viral heVLP systems described herein have the potential to be simpler, more efficient and safer than conventional, artificially-derived lipid/gold nanoparticles and viral particle-based delivery systems because heVLPs are comprised of human-derived components.
  • the cargo inside may or may not be human derived, but the heVLP is entirely comprised from human and synthetic non-immunogenic components.
  • Synthetic components include surface scFv/nanobody/darpin peptides that have been demonstrated to not be immunostimulatory and can be used to enhance targeting and cellular uptake of heVLPs. This means that the exterior surface of the particle lacks components that are significantly immunostimulatory, which should minimize immunogenicity and antibody neutralization of these particles. Excluding cargo, the heVLPs do not contain exogenous viral components inherent to other VLPs and this represents a significant and novel advancement in technology.
  • heVLPs can utilize (but do not require) chemical-based dimerizers, and heVLPs have the ability to package and deliver cargo molecules including therapeutic or diagnostic agents, including biomolecules and chemicals, e.g., specialty single and/or double-stranded DNA molecules (e.g., plasmid, mini circle, closed-ended linear DNA, AAV DNA, episomes, bacteriophage DNA, homology directed repair templates, etc.), single and/or double-stranded RNA molecules (e.g., single guide RNA, prime editing guide RNA, messenger RNA, transfer RNA, long non-coding RNA, circular RNA, RNA replicon, circular or linear splicing RNA, micro RNA, small interfering RNA, short hairpin RNA, piwi-interacting RNA, toehold switch RNA, RNAs that can be bound by RNA binding proteins, bacteriophage RNA, internal ribosomal entry site containing RNA, etc.), proteins, chemical compounds and/or
  • heVLPs described herein are different from conventional retroviral particles, virus-like particles (VLPs), exosomes and other previously described extracellular vesicles that can be loaded with cargo, at least because heVLPs can be produced by a strategic overexpression of human-derived components in human cells, heVLPs have a vast diversity of possible cargos and loading strategies, heVLPs lack a limiting DNA/RNA length constraint, heVLPs lack proteins derived from pol and exogenous gag, and heVLPs have unique mechanisms of cellular entry.
  • compositions and methods for cargo delivery that can be used with a diverse array of protein and nucleic acid molecules, including genome editing, epigenome modulation, transcriptome editing and proteome modulation reagents, that are applicable to many disease therapies.
  • engineered heVLPs comprising a membrane comprising a phospholipid bilayer with one or more HERV-derived ENV/glycoprotein(s) (e.g., overexpressed from exogenous sources, such as plasmids or stably integrated transgenes, in heVLP production cells) (e.g., as shown in Table 1) on the external side; and a human endogenous GAG protein, other plasma membrane recruitment domain, and/or biomolecule/chemical cargo disposed in the core of the heVLP on the inside of the membrane, wherein the biomolecule cargo may or may not be fused to a human-endogenous GAG or other plasma membrane recruitment domain (e.g., as shown in Table 6), and the heVLP does not comprise a non-human gag and/or pol protein, do not express gag and/or pol proteins except for gag proteins that are encoded in the human genome or gag proteins that are encoded by a consensus sequence that is derived from gag proteins found in the human genome
  • the HERV ENV can be truncated or fused to an scFv or other targeting polypeptides.
  • the HERV GAG can be fused to a plasma membrane recruitment domain (e.g., as shown in Table 6).
  • engineered heVLPs comprise a membrane comprising a phospholipid bilayer with one or more HERV-derived ENV/glycoprotein(s) (e.g., overexpressed from exogenous sources, such as plasmids or stably integrated transgenes, in heVLP production cells) (e.g., as shown in Table 1) on the external side; and, if desired, a plasma membrane recruitment domain (e.g., as shown in Table 6); and, if desired a biomolecule/chemical cargo inside the particle.
  • HERV-derived ENV/glycoprotein(s) e.g., overexpressed from exogenous sources, such as plasmids or stably integrated transgenes, in heVLP production cells
  • a plasma membrane recruitment domain e.g., as shown in Table 6
  • a heVLP comprising a biomolecular cargo.
  • the methods include providing a cell expressing (e.g., engineered to express or overexpress) one or more HERV-derived envelope proteins (e.g., as shown in Table 1), and a cargo, wherein the cell does not express a gag and/or pol protein, except for gag proteins that are encoded in the human genome or gag proteins that are encoded by a consensus sequence that is derived from gag proteins found in the human genome; and maintaining the cell under conditions such that the cells produce heVLPs.
  • the methods further include harvesting and optionally purifying and/or concentrating the produced heVLPs.
  • cells e.g., isolated cells, preferably mammalian, e.g., human, cells
  • express e.g., that have been induced to overexpress, in combination one or more HERV-derived envelope proteins (e.g., (overexpressed from exogenous sources, such as plasmids or stably integrated transgenes)(e.g., as shown in Table 1), and a cargo fused to a human endogenous GAG or other plasma membrane recruitment domain (e.g., as shown in Table 6), wherein the cell does not express a gag protein except for gag proteins that are encoded in the human genome or gag proteins that are encoded by a consensus sequence that is derived from gag proteins found in the human genome (overexpressed from exogenous sources, such as plasmids or stably integrated transgenes)).
  • HERV-derived envelope proteins e.g., (overexpressed from exogenous sources, such as plasmids or stably integrated transgenes)(e
  • the cells are primary or stable human cell lines, e.g., Human Embryonic Kidney (HEK) 293 cells, HEK293 T cells, or BeWo cells.
  • HEK Human Embryonic Kidney
  • the cells can be used to produce heVLPs as described herein.
  • the methods include using cells that have or have not been manipulated to express any exogenous proteins except for a HERV envelope (e.g., as shown in Table 1), and, if desired, a plasma membrane recruitment domain (e.g., as shown in Table 6).
  • the “empty” particles that are produced can be loaded with biomolecule or chemical molecule cargo by utilizing nucleofection, lipid, polymer, or CaCl 2 transfection, sonication, freeze thaw, and/or heat shock of purified particles mixed with cargo.
  • producer cells do not express any human exogenous gag protein. This type of loading allows for cargo to be unmodified by fusions to plasma membrane recruitment domains and represents a significant advancement from previous VLP technology.
  • heVLPs that contain cargo are produced and isolated can be loaded with additional biomolecule or chemical molecule cargo by utilizing nucleofection, lipid, polymer, or CaCl 2 transfection, sonication, freeze thaw, incubation at various temperatures, and/or heat shock of purified particles mixed with cargo.
  • the cargo is a therapeutic or diagnostic protein or nucleic acid encoding a therapeutic or diagnostic protein.
  • the cargo is a chemical compound or molecule.
  • the chemical molecule is a trigger for protein-protein dimerization of multimerization, such as the A/C heterodimerizer or rapamycin.
  • the chemical compound is a DNA PK inhibitor, such as M3814, NU7026, or NU7441 which potently enhance homology directed repair gene editing.
  • the biomolecule cargo is a gene editing reagent.
  • the gene editing reagent comprises a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; a nucleic acid encoding a zinc finger (ZF), transcription activator-like effector (TALE), and/or CRISPR-based genome editing or modulating protein; or a riboucleoprotein complex (RNP) comprising a CRISPR-based genome editing or modulating protein.
  • ZF zinc finger
  • TALE transcription activator-like effector
  • RNP riboucleoprotein complex
  • the gene editing reagent is selected from the proteins listed in Tables 2, 3, 4 & 5.
  • the gene editing reagent comprises a CRISPR-based genome editing or modulating protein
  • the heVLP further comprises one or more guide RNAs that bind to and direct the CRISPR-based genome editing or modulating protein to a target sequence.
  • the cargo comprises a covalent or non-covalent connection to a human-endogenous GAG or other plasma membrane recruitment domain, preferably as shown in Table 6.
  • Covalent connections for example, can include direct protein-protein fusions generated from a single reading frame, inteins that can form peptide bonds, other proteins that can form covalent connections at R-groups and/or RNA splicing.
  • Non-covalent connections can include DNA/DNA, DNA/RNA, and/or RNA/RNA hybrids (nucleic acids base pairing to other nucleic acids via hydrogen-bonding interactions), protein domains that dimerize or multimerize with or without the need for a chemical compound/molecule to induce the protein-protein binding, single chain variable fragments, nanobodies, affibodies, proteins that bind to DNA and/or RNA, proteins with quaternary structural interactions, optogenetic protein domains that can dimerize or multimerize in the presence of certain light wavelengths, and/or naturally reconstituting split proteins.
  • the cargo comprises a fusion to a dimerization domain or protein-protein binding domain that may or may not require a molecule to trigger dimerization or protein-protein binding.
  • the producer cells are FDA-approved cells lines, allogenic cells, and/or autologous cells derived from a donor.
  • the full or active peptide domains of human CD47 may be incorporated in the heVLP surface to reduce immunogenicity.
  • AAV proteins included here are AAV REP 52, REP 78, and VP1-3.
  • the capsid site where proteins can be inserted is T138 starting from the VP1 amino acid counting. Dimerization domains could be inserted at this point in the capsid, for instance.
  • dimerization domains included here that may or may not need a small molecule inducer are dDZF1, dDZF2, DmrA, DmrB, DmrC, FKBP, FRB, GCN4 scFv, 10 ⁇ /24 ⁇ GCN4, GFP nanobody and GFP.
  • split inteins examples include Npu DnaE, Cfa, Vma, and Ssp DnaE.
  • RNA binding proteins examples include MS2, Com, and PP7.
  • Examples of synthetic DNA-binding zinc fingers included here are ZF6/10, ZF8/7, ZF9, MK10, Zinc Finger 268, and Zinc Finger 268/NRE.
  • proteins that multimerize as a result of quaternary structure included here are E. coli ferritin, and the other chimeric forms of ferritin.
  • optogenetic “light-inducible proteins” examples include Cry2, CIBN, and Lov2-Ja.
  • peptides the enhance transduction included here are L17E, Vectofusin, KALA, and the various forms of nisin.
  • FIG. 1 Depiction of exemplary T2heVLP/T4heVLP production and transduction for RNP/protein delivery. All heVLP expression constructs are stably integrated in the genome of the producer cell.
  • Construct 1-0 corresponds to the human-endogenous GAG (hGAG).
  • Construct 1-1 corresponds to the human-endogenous GAG or other phospholipid bilayer recruitment domain.
  • 1-2 corresponds to the cargo.
  • 2 corresponds to an optional guide RNA.
  • 1-0, 1-1 and 1-2 are translated in the cytosol where the fusion of 1-1 and 1-2 complexes with guide RNA before it is recruited to the phospholipid bilayer.
  • 3 corresponds to a HERV-derived glycoprotein (hENV).
  • the HERV-derived glycoprotein is expressed as a transmembrane protein on the plasma membrane.
  • hGAG drives budding of cargo-containing heVLPs from the plasma membrane to extracellular space. These particles are purified and are able to fuse with target cells and deliver cargo by interacting with surface receptors at the target cell surface.
  • FIG. 2 Depiction of purified heVLPs entering a target cell and delivering cargo to the cytosol.
  • the human-endogenous GAG or other phospholipid bilayer recruitment domain allows cargo to enter the target cell nucleus as long as cargo possesses a nuclear localization sequence.
  • FIG. 3 Exemplary T1heVLP-delivered spCas9 genome editing in vitro.
  • HEK 293T cells transduced with T1heVLPs containing PLC PH fused to spCas9, hGAGK con fused to spCas9, or human Activity-regulated cytoskeleton-associated protein (hArc) fused to spCas9 targeted to VEGF site #3.
  • heVLPs are pseudotyped with either hENVW (left chart) or hENVFRD (right chart). Gene modification is measured by amplicon sequencing.
  • FIG. 4 Depiction of T1heVLP/T3heVLP production. Plasmid DNA constructs involved in the transfection encode cargo, an optional guide RNA, hGAG and a HERV-derived glycoprotein. Plasmids, or other types of DNA molecules, will be distributed throughout the production cell, so constructs located in the nucleus will express heVLP components and cargo, and constructs located near the plasma membrane or endosomes will be encapsulated within budding heVLPs.
  • FIG. 5 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle either by producer cells expressing cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 6 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle either by producer cells expressing cargo-gag fusion or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 7 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle either by producer cells expressing cargo-PH fusion or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 8 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle either by producer cells expressing cargo-gag/PH fusion or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 9 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of a dimerization molecule (A/C heterodimerizer) either by producer cells expressing cargo and gag fused to DmrA or DmrC or particles being loaded by various particle loading methods described herein, such as electroporation.
  • a dimerization molecule A/C heterodimerizer
  • FIG. 10 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of a dimerization molecule (A/C heterodimerizer) either by producer cells expressing cargo and PH fused to DmrA or DmrC or particles being loaded by various particle loading methods described herein, such as electroporation.
  • a dimerization molecule A/C heterodimerizer
  • FIG. 11 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of a dimerization molecule (A/C heterodimerizer) either by producer cells expressing cargo and gag/PH fused to DmrA or DmrC or particles being loaded by various particle loading methods described herein, such as electroporation.
  • a dimerization molecule A/C heterodimerizer
  • FIG. 12 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle either by producer cells expressing cargo and gag fused to an RNA binding protein (RBP), MS2, that binds to its MS2 RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • RBP RNA binding protein
  • MS2 that binds to its MS2 RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 13 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo was packaged inside the particle either by producer cells expressing cargo and PH fused to an RNA binding protein (RBP), MS2, that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • RBP RNA binding protein
  • MS2 that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 14 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo was packaged inside the particle either by producer cells expressing cargo and gag/PH fused to an RNA binding protein (RBP), MS2, that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • RBP RNA binding protein
  • MS2 that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 15 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of dimerization molecule (A/C Heterodimerizer) either by producer cells expressing cargo and gag and an RNA binding protein (RBP), MS2, fused to DmrA or DmrC that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • A/C Heterodimerizer dimerization molecule
  • RBP RNA binding protein
  • MS2 RNA binding protein
  • FIG. 16 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of dimerization molecule (A/C Heterodimerizer) either by producer cells expressing cargo and PH and an RNA binding protein (RBP), MS2, fused to DmrA or DmrC that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • A/C Heterodimerizer dimerization molecule
  • RBP RNA binding protein
  • MS2 fused to DmrA or DmrC that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 17 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of dimerization molecule (A/C Heterodimerizer) either by producer cells expressing cargo and gag/PH and an RNA binding protein (RBP), MS2, fused to DmrA or DmrC that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • A/C Heterodimerizer dimerization molecule
  • RBP RNA binding protein
  • MS2 fused to DmrA or DmrC that binds to its RNA stem loop (MS2 SL) that is complexed with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 18 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle either by producer cells expressing cargo and gag fused to a repetitive GCN4 domain that is bound by an scFv that is fused with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 19 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle either by producer cells expressing cargo and PH fused to a repetitive GCN4 domain that is bound by an scFv that is fused with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 20 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle either by producer cells expressing cargo and gag/PH fused to a repetitive GCN4 domain that is bound by an scFv that is fused with cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 21 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of a dimerization molecule (A/C Heterodimerizer) by producer cells expressing gag and a repetitive GCN4 domain that are fused to DmrA or DmrC. GCN4 is bound by an scFv that is fused with cargo that is also being expressed in producer cells. Particles could also be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 22 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of a dimerization molecule (A/C Heterodimerizer) by producer cells expressing PH and a repetitive GCN4 domain that are fused to DmrA or DmrC. GCN4 is bound by an scFv that is fused with cargo that is also being expressed in producer cells. Particles could also be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 23 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein. Cargo was packaged inside the particle in the presence of a dimerization molecule (A/C Heterodimerizer) by producer cells expressing gag/PH and a repetitive GCN4 domain that are fused to DmrA or DmrC. GCN4 is bound by an scFv that is fused with cargo that is also being expressed in producer cells. Particles could also be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 24 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles
  • FIG. 25 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles
  • FIG. 26 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles
  • FIG. 27 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles
  • FIG. 28 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles with DmrB inserted in the Capsid protein, VP2
  • DmrB dimerizer molecule was packaged inside the particle in the presence of DmrB dimerizer molecule either by producer cells expressing cargo and gag fused to DmrB or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 29 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles with DmrB inserted in the Capsid protein, VP2
  • DmrB dimerizer molecule was packaged inside the particle in the presence of DmrB dimerizer molecule either by producer cells expressing cargo and PH fused to DmrB or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 30 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles with DmrB inserted in the Capsid protein, VP2
  • DmrB dimerizer molecule was packaged inside the particle in the presence of DmrB dimerizer molecule either by producer cells expressing cargo and gag/PH fused to DmrB or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 31 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles with DmrB inserted in the Capsid protein, VP2
  • DmrB dimerizer and A/C Heterodimerizer molecules either by producer cells expressing cargo and gag fused to DmrA, DmrB, or DmrC, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 32 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles with DmrB inserted in the Capsid protein, VP2
  • DmrB dimerizer and A/C Heterodimerizer molecules either by producer cells expressing cargo and PH fused to DmrA, DmrB, or DmrC, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 33 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo AAV particles with DmrB inserted in the Capsid protein, VP2
  • DmrB dimerizer and A/C Heterodimerizer molecules either by producer cells expressing cargo and gag/PH fused to DmrA, DmrB, or DmrC, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 34 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo single-stranded DNA
  • FIG. 35 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag.
  • Cargo single-stranded DNA
  • FIG. 36 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and PH.
  • Cargo single-stranded DNA
  • FIG. 37 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag/PH.
  • Cargo single-stranded DNA
  • FIG. 38 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo double-stranded DNA
  • FIG. 39 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag.
  • Cargo double-stranded DNA
  • FIG. 40 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and PH.
  • Cargo double-stranded DNA
  • FIG. 41 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag/PH.
  • Cargo double-stranded DNA
  • FIG. 42 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag fused to a zinc finger protein (ZFP) that will bind a specific sequence in the cargo.
  • Cargo double-stranded DNA
  • FIG. 43 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and PH fused to a zinc finger protein (ZFP) that will bind a specific sequence in the cargo.
  • ZFP zinc finger protein
  • Cargo double-stranded DNA
  • FIG. 44 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag/PH fused to a zinc finger protein (ZFP) that will bind a specific sequence in the cargo.
  • Cargo double-stranded DNA
  • FIG. 45 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag and a zinc finger protein (ZFP) that will bind a specific sequence in the cargo fused to DmrA or DmrC in the presence of A/C Heterodimerizer molecule.
  • Cargo double-stranded DNA
  • FIG. 46 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and PH and a zinc finger protein (ZFP) that will bind a specific sequence in the cargo fused to DmrA or DmrC in the presence of A/C Heterodimerizer molecule.
  • Cargo double-stranded DNA
  • FIG. 47 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag/PH and a zinc finger protein (ZFP) that will bind a specific sequence in the cargo fused to DmrA or DmrC in the presence of A/C Heterodimerizer molecule.
  • Cargo double-stranded DNA
  • FIG. 48 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag fused to a zinc finger protein (ZFP) that will bind a specific sequence in the cargo.
  • Cargo double-stranded DNA bound by Cas9 RNP-ZFP fusion
  • Cas9 RNP-ZFP fusion could be expressed by the producer cells and the particles could be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 49 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and PH fused to a zinc finger protein (ZFP) that will bind a specific sequence in the cargo.
  • Cargo double-stranded DNA bound by Cas9 RNP-ZFP fusion
  • Cas9 RNP-ZFP fusion could be expressed by the producer cells and the particles could be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 50 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag/PH fused to a zinc finger protein (ZFP) that will bind a specific sequence in the cargo.
  • Cargo double-stranded DNA bound by Cas9 RNP-ZFP fusion
  • Cas9 RNP-ZFP fusion could be expressed by the producer cells and the particles could be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 51 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag fused to a zinc finger protein (ZFP) fused to DmrA or DmrC that will bind a specific sequence in the cargo in the presence of A/C Heterodimerizer molecule.
  • Cargo double-stranded DNA bound by Cas9 RNP-ZFP fusion
  • the Cas9 RNP-ZFP fusion could be expressed by the producer cells and the particles could be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 52 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and PH fused to a zinc finger protein (ZFP) fused to DmrA or DmrC that will bind a specific sequence in the cargo in the presence of A/C Heterodimerizer molecule.
  • Cargo double-stranded DNA bound by Cas9 RNP-ZFP fusion
  • the Cas9 RNP-ZFP fusion could be expressed by the producer cells and the particles could be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 53 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein and gag/PH fused to a zinc finger protein (ZFP) fused to DmrA or DmrC that will bind a specific sequence in the cargo in the presence of A/C Heterodimerizer molecule.
  • Cargo double-stranded DNA bound by Cas9 RNP-ZFP fusion
  • Cas9 RNP-ZFP fusion could be expressed by the producer cells and the particles could be loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 54 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA was packaged inside the particle either by producer cells expressing cargo or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 55 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA was packaged inside the particle either by producer cells expressing cargo and gag or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 56 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA was packaged inside the particle either by producer cells expressing cargo and PH or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 57 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA was packaged inside the particle either by producer cells expressing cargo and gag/PH or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 58 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with MS2 stem loop(s) was packaged inside the particle either by producer cells expressing cargo and gag fused to MS2 or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 59 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with MS2 stem loop(s) was packaged inside the particle either by producer cells expressing cargo and PH fused to MS2 or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 60 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with MS2 stem loop(s) was packaged inside the particle either by producer cells expressing cargo and gag/PH fused to MS2 or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 61 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with MS2 stem loop(s) was packaged inside the particle either by producer cells expressing cargo and gag and MS2 fused to DmrA or DmrC in the presence of A/C heterodimerizer, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 62 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with MS2 stem loop(s) was packaged inside the particle either by producer cells expressing cargo and PH and MS2 fused to DmrA or DmrC in the presence of A/C heterodimerizer, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 63 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with MS2 stem loop(s) was packaged inside the particle either by producer cells expressing cargo and gag/PH and MS2 fused to DmrA or DmrC in the presence of A/C heterodimerizer, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 64 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with RBP stem loop(s) was packaged inside the particle either by producer cells expressing cargo fused to an RBP and gag fused to another RBP or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 65 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with RBP stem loop(s) was packaged inside the particle either by producer cells expressing cargo fused to an RBP and PH fused to another RBP or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 66 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with RBP stem loop(s) was packaged inside the particle either by producer cells expressing cargo fused to an RBP and gag/PH fused to another RBP or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 67 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with RBP stem loop(s) was packaged inside the particle either by producer cells expressing cargo fused to an RBP and gag and another RBP fused to DmrA or DmrC in the presence of A/C Heterodimerizer molecule, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 68 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with RBP stem loop(s) was packaged inside the particle either by producer cells expressing cargo fused to an RBP and PH and another RBP fused to DmrA or DmrC in the presence of A/C Heterodimerizer molecule, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • FIG. 69 Depiction of exemplary heVLP and cargo configuration
  • This particle was created by producer cells expressing an envelope protein.
  • Cargo RNA with RBP stem loop(s) was packaged inside the particle either by producer cells expressing cargo fused to an RBP and gag/PH and another RBP fused to DmrA or DmrC in the presence of A/C Heterodimerizer molecule, or particles being loaded by various particle loading methods described herein, such as electroporation.
  • Genome editing reagents such as zinc finger nucleases (ZFNs) or RNA-guided, enzymatically active/inactive DNA binding proteins such as Cas9 have undergone rapid advancements in terms of specificity and the types of edits that can be executed, but the hurdle of safe in vivo delivery still precludes efficacious gene editing therapies.
  • ZFNs zinc finger nucleases
  • Cas9 RNA-guided, enzymatically active/inactive DNA binding proteins
  • Cas9 RNA-guided, enzymatically active/inactive DNA binding proteins
  • Retroviral particles such as lentivirus
  • VLPs have been developed that mimic virus particles in their ability to self-assemble, but are not infectious as they lack some of the core viral genes.
  • Both lentiviral and VLP vectors are typically produced by transiently transfecting a producer cell line with plasmids that encode all components necessary to produce lentiviral particles or VLP.
  • One major flaw that we have discovered regarding lentiviral particles and VSVG-based VLPs that are produced by this conventional transient transfection method is that, in addition to their conventional cargo, these particles package and deliver plasmid DNA that was used in the initial transient transfection.
  • This unintended plasmid DNA delivery can be immunogenic and cause undesirable effects, such as plasmid DNA being integrated into genomic DNA. It is important to specify the type of biomolecules and/or chemicals that are to be delivered within particles, and heVLPs have been designed to possess this germane capability.
  • heVLPs described herein can deliver DNA only, DNA+RNA+protein, or RNA+protein.
  • heVLPs are the first VLP delivery modality that leverages select components from human endogenous retroviruses (HERVs) to create particles for customizable cargo delivery into eukaryotic cells.
  • HERVs human endogenous retroviruses
  • heVLPs are capable of controlling the form of the cargo (DNA, protein, and/or RNA). All other previously described VLPs and viral particles package and deliver unwanted plasmid DNA (or other types of DNA-based gene expression constructs) introduced into particle producer cells via transient transfection in addition to the intended protein and/or RNA cargo(s).
  • heVLPs Another non-obvious aspect of heVLPs is the ENV protein on the surface of the heVLP.
  • the ENV protein is responsible for the ability of heVLPs to efficiently deliver cargo into cells.
  • the majority of retroviral ENV proteins require post-translational modifications in the form of proteolytic cleavage of the intracellular domain (ICD) of the ENV protein in order to activate the fusogenicity of the ENV protein; this is essential for infectivity.
  • ICD intracellular domain
  • the envelope proteins described in Table 1 are all derived from HERVs that are expressed to varying levels in healthy human tissues (or HERV ENV consensus sequences). Some of these sequences possess ICD truncations that have been shown to enhance fusogenicity, but most do not require truncation.
  • heVLPs do not require exogenous, virally-derived GAG for particle formation because heVLPs utilize human-endogenous GAG proteins from HERVs (or HERV GAG consensus sequences). 1 These HERV GAG proteins enable heVLP formation and are expressed to varying levels in healthy human tissues. Importantly, heVLPs are different from previously described viral particles, VLPs, and extracellular vesicles because heVLPs are composed of a novel combination of HERV ENV and GAG components, and heVLPs lack components from exogenous viruses. 2,3 Because of the above mentioned design optimizations, heVLPs are particularly suited for delivery of DNA, RNA, protein, or combinations of biomolecules and/or chemicals, such as DNA-encoded or RNP-based genome editing reagents.
  • Genome editing reagents especially CRISPR-CAS, zinc finger, and TAL-nuclease-based reagents have the potential to become in vivo therapeutics for the treatment of genetic diseases, but techniques for delivering genome editing reagents into cells are severely limiting or unsafe for patients.
  • Conventional therapeutic monoclonal antibody delivery is successful at utilizing direct injection for proteins.
  • strategies for direct injection of gene editing proteins, such as Cas9 are hampered by immunogenicity, degradation, ineffective cell specificity, and inability to cross the plasma membrane or escape endosomes/lysosomes. 4-10 More broad applications of protein therapy and gene editing could be achieved by delivering therapeutic protein cargo to the inside of cells.
  • Cas9 for example, cannot efficiently cross the phospholipid bilayer to enter into cells, and has been shown to have innate and adaptive immunogenic potential. 4-8 Therefore, it is not practical or favorable to deliver Cas9 by direct injection or as an external/internal conjugate to lipid, protein or metal-based nanoparticles that have cytotoxic and immunogenic properties and often yield low levels of desired gene modifications. 9-20
  • Nanoparticles that encapsulate cargo are another delivery strategy that can be used to deliver DNA, protein, RNA and RNPs into cells 9-18 Nanoparticles can be engineered for cell specificity and can trigger endocytosis and subsequent endosome lysis. However, nanoparticles can have varying levels of immunogenicity due to an artificially-derived vehicle shell. 9-20 Many nanoparticles rely on strong opposing charge distributions to maintain particle structural integrity, and the electrostatics can make it toxic and unfit for many in vivo therapeutic scenarios. 9 Nanoparticles that deliver RNA have had successes in recent clinical trials, but most have only been used to deliver siRNA or shRNA. Toxicity from such nanoparticles is still a major concern.
  • Nanoparticles that deliver mRNA coding for genome editing RNPs have also been a recent success, but these create a higher number of off-target effects compared to protein delivery and RNA stability is lower than that of protein. 17 Nanoparticles that deliver genome editing RNPs and DNA have been a significant breakthrough because they can leverage both homology directed repair (HDR) and non-homologous end joining (NHEJ), but exhibit prohibitively low gene modification frequencies in vitro and in vivo, and therefore currently have limited applications in vivo as a gene editing therapeutic. 15
  • HDR homology directed repair
  • NHEJ non-homologous end joining
  • AAV vectors are a promising delivery modality that can successfully deliver DNA into eukaryotic cells
  • AAV cannot efficiently package and deliver DNA constructs larger than 4.5 kb and this precludes delivery of many CRISPR-based gene editing reagents that require larger DNA expression constructs.
  • CRISPR-based gene editing reagents can be split into multiple different AAV particles, but this strategy drastically reduces delivery and editing efficiency.
  • AAV and adenoviral vectors can have varying levels of immunogenicity.
  • inverted-terminal repeats in the AAV DNA construct can promote the formation of spontaneous episomes leading to prolonged expression of genome editing reagents and increased off-target effects. ITRs can also promote the undesired integration of AAV DNA into genomic DNA. 21-24
  • VLPs have been utilized to deliver mRNA and protein cargo into the cytosol of cells. 2,3,25-30 VLPs have emerged as a substitute delivery modality for retroviral particles. VLPs can be designed to lack the ability to integrate retroviral DNA, and to package and deliver protein/RNP/DNA. However, most VLPs, including recently conceived VLPs that deliver genome editing reagents known to date, utilize HIV or other virally-derived gag-pol protein fusions and viral proteases to generate retroviral-like particles. 25-27,29,30 Secondly, some VLPs containing RGNs also must package and express guide RNAs from a lentiviral DNA transcript.
  • VLPs require a viral protease in order to form functional particles and release genome editing cargo.
  • 25-27,29 Since this viral protease recognizes and cleaves at multiple amino acid motifs, it can cause damage to the protein cargo which could be hazardous for therapeutic applications.
  • most published VLP modalities that deliver genome editing proteins to date exhibit low in vitro and in vivo gene modification efficiencies due to low packaging and transduction efficiency.
  • 25-27 Fifthly, the complex viral genomes utilized for these VLP components possess multiple reading frames and employ RNA splicing that could result in spurious fusion protein products being delivered.
  • Extracellular vesicles are another delivery modality that can package and deliver cargo within exosomes and ectosomes. 31,32 Similar to VLPs, extracellular vesicles are comprised of a phospholipid bilayer from a mammalian cell. Unlike VLPs, extracellular vesicles lack viral components and therefore have limited immunogenicity. Whereas VLPs have a great ability to enter cells due to external fusogenic glycoproteins (VSVG) extracellular vesicles mainly rely on cellular uptake via micropinocytosis and this limits the delivery efficiency of extracellular vesicles.
  • VSVG fusogenic glycoproteins
  • heVLPs try to leverage the delivery benefits of extracellular vesicles and VLPs.
  • heVLPs are the first VLP modality to eliminate all the potentially harmful exogenous, virally-derived components.
  • heVLP components are known to be involved in extracellular vesicle biogenesis, they are known to possess local immunosuppressive properties, and their expression in healthy human tissues minimizes the chance of eliciting an immune response because of central tolerance.
  • heVLPs are a safer and more effective alternative than previously described VLPs, extracellular vesicles, AAVs and nanoparticles-especially for delivery of genome editing reagents-because heVLPs are comprised of all human-derived components, heVLPs have the ability to deliver DNA+RNP, or RNP alone while other previously described VLPs cannot prevent transient transfection DNA from being unintentionally packaged and delivered, heVLPs can deliver specialty DNA molecules while previously described VLPs, nanoparticles and AAVs cannot or do not, and heVLPs can be produced with cells that have been derived from patients (autologous heVLPs) and other FDA-approved cell lines (allogenic heVLPs) to further reduce the risks of adverse immune reactions.
  • Streptococcus pyogenes Cas9 spCas9
  • Acidaminococcus sp. Cas12a functionalize are two of the most popular RNA-guided enzymes for editing that leverages NHEJ for introducing stop codons or deletions, or HDR for causing insertions.
  • this invention provides a novel way of packaging and delivering reagents for applications of genome editing, epigenome modulation, transcriptome editing and proteome modulation. Importantly, this invention is also the first to address the phenomenon of inadvertent DNA delivery in VLPs and the first to control for the type of biomolecule to be delivered (DNA, RNA, and/or protein) thereby increasing the types of therapeutic in vivo genome modifications that are possible and minimizing deleterious off target effects.
  • Section 1 heVLP-Mediated Delivery of Cargo Including DNAs, Proteins, Compounds, and RNAs
  • VLPs that have been engineered to encapsulate and deliver protein-based cargo commonly fuse cargo to the INT or GAG polyprotein. 25-27,29,30,39,40 After transient transfection of production plasmid DNA constructs, these protein fusions are translated in the cytosol of conventional VLP production cell lines, the gag matrix is acetylated and recruited to the cell membrane, and the gag fusions are encapsulated (transient transfection DNA is also unintentionally encapsulated) within VLPs as VLPs bud off of the membrane into extracellular space.
  • the heVLPs described herein can package protein-based cargo by integrating all production DNA into the genomic DNA of production cell lines. Once cell lines are created, protein delivery heVLPs can be produced in a constitutive or inducible fashion. Proteins are packaged into heVLP by fusing select human-endogenous GAG proteins or other plasma membrane recruitment domains to protein-based cargo (e.g., as shown in Table 6). Human-endogenous GAG proteins and human pleckstrin homology (PH) domains localize to biological membranes. PH domains interact with phosphatidylinositol lipids and proteins within biological membranes, such as PIP2, PIPS, ⁇ -subunits of GPCRs, and PKC.
  • PIP2 phosphatidylinositol lipids and proteins within biological membranes
  • human-endogenous GAG proteins drive budding and particle formation.
  • This dual functionality of human-endogenous GAG enables packaging of cargo and budding/formation of particles.
  • One such human-endogenous GAG protein used for this purpose is the human Arc protein can be fused to protein-based cargo to recruit cargo to the cytosolic side of the phospholipid bilayer.
  • These human-endogenous GAG phospholipid bilayer recruitment domains can be fused to the N-terminus or C-terminus of protein-based cargo via polypeptide linkers of variable length regardless of the location or locations of one or more nuclear localization sequence(s) (NLS) within the cargo.
  • NLS nuclear localization sequence
  • the linker between protein-based cargo and the human-endogenous GAG phospholipid bilayer recruitment domain is a polypeptide linker 5-20, e.g., 8-12, e.g., 10, amino acids in length primarily composed of glycines and serines.
  • the human-endogenous GAG or other phospholipid bilayer recruitment domain localizes the cargo to the phospholipid bilayer and this protein cargo is packaged within heVLPs that bud off from the producer cell into extracellular space ( FIG. 1 ).
  • the use of these human-endogenous GAG and other phospholipid bilayer recruitment domains is novel and unique in that these human-endogenous GAG and other proteins can facilitate for localization of cargo to the cytosolic face of the plasma membrane within the heVLP production cells, and they also allow for cargo to localize to the nucleus of heVLP-transduced cells without the utilization of exogenous retroviral GAG or chemical and/or light-based dimerization systems ( FIG. 2 ).
  • the heVLP delivery of Cas9 for example, is significantly more efficient with a fusion to a human-endogenous GAG protein compared to a fusion to a PH plasma membrane recruitment domain or no fusion at all ( FIG. 3 ).
  • heVLPs can also package and deliver a combination of DNA and RNA if heVLPs are produced via transient transfection of a production cell line.
  • DNA that is transfected into cells will possess size-dependent mobility such that a fraction of the transfected DNA will remain in the cytosol while another fraction of the transfected DNA will localize to the nucleus.
  • 44-46 One fraction of the transfected DNA in the nucleus will expressed components needed to create heVLPs and the other fraction in the cytosol/near the plasma membrane will be encapsulated and delivered in heVLPs ( FIG. 4 ).
  • heVLP “Cargo” as used herein can refer to a one or more of chemicals, e.g., small molecule compounds, combination of DNA, RNA, and protein, a combination of RNA and protein, a combination of DNA and protein, or protein, e.g., for therapeutic or diagnostic use, or for the applications of genome editing, epigenome modulation, and/or transcriptome modulation.
  • chemicals e.g., small molecule compounds, combination of DNA, RNA, and protein, a combination of RNA and protein, a combination of DNA and protein, or protein, e.g., for therapeutic or diagnostic use, or for the applications of genome editing, epigenome modulation, and/or transcriptome modulation.
  • endogenous RNA and protein from the producer cells get packaged and/or incorporated into heVLPs.
  • T1heVLPs type 1 cargo
  • exogenous RNA and protein exogenous and/or endogenous protein
  • type 2 cargo T2heVLPs
  • T3heVLPs type 3 cargo
  • proteins exogenous and/or endogenous protein
  • T1 contains DNA, RNA, +/ ⁇ exogenous protein
  • T2 contains RNA+/ ⁇ exogenous protein
  • T3 contains DNA+/ ⁇ exogenous protein
  • T4 is a particle with or without exogenous protein cargo.
  • T4 without exogenous protein is considered an “empty particle” because there is no “exogenous cargo.”
  • “Exogenous cargo” is cargo not endogenous to the producer cells that can be packaged and/or incorporated into heVLPs.
  • T1-T4heVLPs can package exogenous chemical molecules in addition to the types of cargoes present in T1-T4heVLPs.
  • RNA in this context could be single guide RNA (sgRNA), Clustered Regularly Interspaced Palindromic Repeat (CRISPR) RNA (crRNA), and/or mRNA coding for cargo.
  • sgRNA single guide RNA
  • CRISPR Clustered Regularly Interspaced Palindromic Repeat
  • crRNA Clustered Regularly Inters
  • small molecules refers to small organic or inorganic molecules of molecular weight below about 3,000 Daltons.
  • small molecules useful for the invention have a molecular weight of less than 3,000 Daltons (Da).
  • the small molecules can be, e.g., from at least about 100 Da to about 3,000 Da (e.g., between about 100 to about 3,000 Da, about 100 to about 2500 Da, about 100 to about 2,000 Da, about 100 to about 1,750 Da, about 100 to about 1,500 Da, about 100 to about 1,250 Da, about 100 to about 1,000 Da, about 100 to about 750 Da, about 100 to about 500 Da, about 200 to about 1500, about 500 to about 1000, about 300 to about 1000 Da, or about 100 to about 250 Da).
  • the cargo is limited by the diameter of the particles, e.g., which in some embodiments range from 150 nm to 500 nm.
  • Nucleases include FokI and AcuI ZFNs and Transcription activator-like effector nucleases (TALENs) and CRISPR based nucleases or a functional derivative thereof (e.g., as shown in Table 2)
  • ZFNs are described, for example, in United States Patent Publications 20030232410; 20050208489; 20050026157; 20050064474; 20060188987; 20060063231; and International Publication WO 07/014275
  • TALENs are described, for example, in United States Patent Publication U.S. Pat. No.
  • Base editors that are described by this work include any CRISPR based nuclease orthologs (wt, nickase, or catalytically inactive (CI)), e.g., as shown in Table 2, fused at the N-terminus to a deaminase or a functional derivative thereof (e.g., as shown in Table 3) with or without a fusion at the C-terminus to one or multiple uracil glycosylase inhibitors (UGIs) using polypeptide linkers of variable length (Base editors are described, for example, in United States Patent Publications US20150166982A1; US20180312825A1; U.S. Ser. No.
  • Prime editors are also compatible with heVLP delivery modalities (Prime editors are described, for example, in Anzalone et al., Nature. 2019 December; 576(7785):149-157).
  • sgRNAs complex with genome editing reagents during the packaging process and are co-delivered within heVLPs.
  • this concept has been validated in vitro by experiments that demonstrate the T2heVLP delivery of RGN RNP for the purposes of site specific editing of an endogenous site ( FIG. 3 ).
  • T2heVLPs have been used to deliver Cas9 RNP to HEK 293T cells for the purposes of editing endogenous VEGF site #3 ( FIG. 3 ).
  • Cargo designed for the purposes of epigenome modulation includes the CI CRISPR based nucleases, zinc fingers (ZFs) and TALEs fused to an epigenome modulator or combination of epigenome modulators or a functional derivative thereof connected together by one or more variable length polypeptide linkers (Tables 2 & 4).
  • T1-T4 cargo designed for the purposes of transcriptome editing includes CRISPR based nucleases or any functional derivatives thereof in Table 5 or CI CRISPR based nucleases or any functional derivatives thereof in Table 5 fused to deaminases in Table 3 by one or more variable length polypeptide linkers.
  • the cargo can also include any therapeutically or diagnostically useful protein, DNA, RNP, or combination of DNA, protein and/or RNP. See, e.g., WO2014005219; U.S. Ser. No. 10/137,206; US20180339166; U.S. Pat. No. 5,892,020A; EP2134841B1; WO2007020965A1.
  • cargo encoding or composed of nuclease or base editor proteins or RNPs or derivatives thereof can be delivered to retinal cells for the purposes of correcting a splice site defect responsible for Leber Congenital Amaurosis type 10.
  • heVLP delivery of base editing reagents or HDR promoting cargo to sensory cells such as cochlear supporting cells and hair cells for the purposes of editing ⁇ -catenin ( ⁇ -catenin Ser 33 edited to Tyr, Pro, or Cys) in order to better stabilize ⁇ -catenin could help reverse hearing loss.
  • heVLP delivery of RNA editing reagents or proteome perturbing reagents could cause a transitory reduction in cellular levels of one or more specific proteins of interest (potentially at a systemic level, in a specific organ or a specific subset of cells, such as a tumor), and this could create a therapeutically actionable window when secondary drug(s) could be administered (this secondary drug is more effective in the absence of the protein of interest or in the presence of lower levels of the protein of interest).
  • heVLP delivery of RNA editing reagents or proteome perturbing reagents could trigger targeted degradation of MAPK and PI3K/AKT proteins and related mRNAs in vemurafenib/dabrafenib-resistant BRAF-driven tumor cells, and this could open a window for the administration of vemurafenib/dabrafenib because BRAF inhibitor resistance is temporarily abolished (resistance mechanisms based in the MAPK/PI3K/AKT pathways are temporarily downregulated by heVLP cargo).
  • This example is especially pertinent when combined with heVLPs that are antigen inducible and therefore specific for tumor cells.
  • heVLPs could deliver Yamanaka factors Oct3/4, Sox2, Klf4, and c-Myc to human or mouse fibroblasts in order to generate induced pluripotent stem cells.
  • heVLPs could deliver dominant-negative forms of proteins in order to elicit a therapeutic effect.
  • heVLPs that are antigen-specific could be targeted to cancer cells in order to deliver proapoptotic proteins BIM, BID, PUMA, NOXA, BAD, BIK, BAX, BAK and/or HRK in order to trigger apoptosis of cancer cells.
  • pancreatic cancer patients present with unresectable disease. Around 30% of patients with unresectable pancreatic tumors will die from local disease progression, so it is desirable to treat locally advanced pancreatic tumors with ablative radiation, but the intestinal tract cannot tolerate high doses of radiation needed to cause tumor ablation. Selective radioprotection of the intestinal tract enables ablative radiation therapy of pancreatic tumors while minimizing damage done to the surrounding gastrointestinal tract.
  • heVLPs could be loaded with dCas9 fused to the transcriptional repressor KRAB and guide RNA targeting EGLN. EGLN inhibition has been shown to significantly reduce gastrointestinal toxicity from ablative radiation treatments because it causes selective radioprotection of the gastrointestinal tract but not the pancreatic tumor. 47
  • Unbound steroid receptors reside in the cytosol. After binding to ligands, these receptors will translocate to the nucleus and initiate transcription of response genes.
  • heVLPs could deliver single chain variable fragment (scFv) antibodies to the cytosol of cells that bind to and disrupt cytosolic steroid receptors.
  • scFv single chain variable fragment
  • the scFv could bind to the glucocorticoid receptor and prevent it from binding dexamethasone, and this would prevent transcription of response genes, such as metallothionein IE which has been linked to tumorigenesis.
  • heVLPs can be indicated for treatments that involve targeted disruption of proteins.
  • heVLPs can be utilized for targeting and disrupting proteins in the cytosol of cells by delivering antibodies/scFvs to the cytosol of cells.
  • Delivery of antibodies through the plasma membrane to the cytosol of cells has been notoriously difficult and inefficient. This mode of protein inhibition is similar to how a targeted small molecule binds to and disrupts proteins in the cytosol and could be useful for the treatment of a diverse array of diseases.
  • scFvs are not hampered by these limitations because scFvs can be generated that bind to many different moieties of a protein in order to disrupt catalysis and interactions with other proteins.
  • RAS oncoproteins are implicated across a multitude of cancer subtypes, and RAS is one of the most frequently observed oncogenes in cancer.
  • the International Cancer Genome Consortium found KRAS to be mutated in 95% of their Pancreatic Adenocarcinoma samples.
  • RAS isoforms are known to activate a variety of pathways that are dysregulated in human cancers, like the PI3K and MAPK pathways. Despite the aberrant roles RAS plays in cancer, no efficacious pharmacologic direct or indirect small molecule inhibitors of RAS have been developed and approved for clinical use.
  • One strategy for targeting RAS could be heVLPs that can deliver specifically to cancer cells scFvs that bind to and disrupt the function of multiple RAS isoforms. 49-51
  • FIGS. 5-69 provide exemplary heVLP configurations and non-limiting examples of cargo molecules.
  • heVLPs are produced from producer cell lines that are either transiently transfected with at least one plasmid or stably expressing constructs that have been integrated into the producer cell line genomic DNA.
  • a single plasmid if a single plasmid is used in the transfection, it should comprise sequences encoding one or more HERV-derived glycoproteins (e.g., as shown in Table 1), one or more HERV-derived GAG proteins, cargo (e.g., a therapeutic protein or a gene editing reagent such as a zinc finger, transcription activator-like effector (TALE), and/or CRISPR-based genome editing/modulating protein and/or RNP such as those found in Tables 2, 3, 4 & 5) with a fusion to a human-endogenous GAG or other plasma membrane recruitment domain (e.g., as shown in Table 6), and a guide RNA, if necessary.
  • two to three plasmids are used in the transfection
  • the plasmids, or other types of specialty DNA molecules described above will also preferably include other elements to drive expression or translation of the encoded sequences, e.g., a promoter sequence; an enhancer sequence, e.g., 5′ untranslated region (UTR) or a 3′ UTR; a polyadenylation site; an insulator sequence; or another sequence that increases or controls expression (e.g., an inducible promoter element).
  • a promoter sequence e.g., an enhancer sequence, e.g., 5′ untranslated region (UTR) or a 3′ UTR
  • UTR 5′ untranslated region
  • insulator sequence e.g., insulator sequence that increases or controls expression
  • another sequence that increases or controls expression e.g., an inducible promoter element
  • appropriate producer cell lines are primary or stable human cell lines refractory to the effects of transfection reagents and fusogenic effects due glycoproteins.
  • appropriate cell lines include Human Embryonic Kidney (HEK) 293 cells, HEK293 T/17 SF cells kidney-derived Phoenix-AMPHO cells, and placenta-derived BeWo cells.
  • HEK Human Embryonic Kidney
  • HEK293 T/17 SF cells kidney-derived Phoenix-AMPHO cells
  • placenta-derived BeWo cells placenta-derived BeWo cells.
  • the producer cells can be cultured in classical DMEM under serum conditions, serum-free conditions, or exosome-free serum conditions.
  • T1 and T3heVLPs can be produced from cells that have been derived from patients (autologous heVLPs) and other FDA-approved cell lines (allogenic heVLPs) as long as these cells can be transfected with DNA constructs that encode the aforementioned heVLP production components by various techniques known in the art.
  • the DNA constructs can be designed to overexpress proteins in the producer cell lines.
  • the plasmid backbones for example, used in the transfection can be familiar to those skilled in the art, such as the pCDNA3 backbone that employs the CMV promoter for RNA polymerase II transcripts or the U6 promoter for RNA polymerase III transcripts.
  • Various techniques known in the art may be employed for introducing nucleic acid molecules into producer cells.
  • Such techniques include chemical-facilitated transfection using compounds such as calcium phosphate, cationic lipids, cationic polymers, liposome-mediated transfection, such as cationic liposome like LIPOFECTAMINE (LIPOFECTAMINE 2000 or 3000 and TranslT-X2), polyethyleneimine, non-chemical methods such as electroporation, particle bombardment, or microinjection.
  • compounds such as calcium phosphate, cationic lipids, cationic polymers, liposome-mediated transfection, such as cationic liposome like LIPOFECTAMINE (LIPOFECTAMINE 2000 or 3000 and TranslT-X2), polyethyleneimine, non-chemical methods such as electroporation, particle bombardment, or microinjection.
  • a human producer cell line that stably expresses the necessary heVLP components in a constitutive and/or inducible fashion can be used for production of T2 and T4heVLPs.
  • T2 and T4heVLPs can be produced from cells that have been derived from patients (autologous heVLPs) and other FDA-approved cell lines (allogenic heVLPs) if these cells have been converted into stable cell lines that express the aforementioned heVLP components.
  • the cargo in order for efficient recruitment of cargo into heVLPs, the cargo comprises a covalent or non-covalent connection to a human-endogenous GAG or other plasma membrane recruitment domain, preferably as shown in Table 6.
  • Covalent connections for example, can include direct protein-protein fusions generated from a single reading frame, inteins that can form peptide bonds, other proteins that can form covalent connections at R-groups and/or RNA splicing.
  • Non-covalent connections can include DNA/DNA, DNA/RNA, and/or RNA/RNA hybrids (nucleic acids base pairing to other nucleic acids via hydrogen-bonding interactions), protein domains that dimerize or multimerize with or without the need for a chemical compound/molecule to induce the protein-protein binding (such as DmrA/DmrB/DmrC (Takara Bio), FKBP/FRB, 55 dDZFs, 56 and Leucine zippers 57 ), single chain variable fragments, 58 nanobodies, 59 affibodies, 60 proteins that bind to DNA and/or RNA, proteins with quaternary structural interactions, optogenetic protein domains that can dimerize or multimerize in the presence of certain light wavelengths, 61 and/or naturally reconstituting split proteins. 62
  • the cargo comprises a fusion to a dimerization domain or protein-protein binding domain that may or may not require a molecule to trigger dimerization or protein-protein binding.
  • the producer cells are FDA-approved cells lines, allogenic cells, and/or autologous cells derived from a donor.
  • the full or active peptide domains of human CD47 may be incorporated in the heVLP surface to reduce immunogenicity.
  • AAV proteins included here are AAV REP 52, REP 78, and VP1-3.
  • the capsid site where proteins can be inserted is T138 starting from the VP1 amino acid counting. 63 Dimerization domains could be inserted at this point in the capsid, for instance.
  • dimerization domains included here that may or may not need a small molecule inducer are dDZF1, 56 dDZF2, 56 DmrA (Takara Bio), DmrB (Takara Bio), DmrC (Takara Bio), FKBP, 55 FRB, 55 GCN4 scFv, 58 10 ⁇ /24 ⁇ GCN4, 58 GFP nanobody 59 and GFP. 64
  • split inteins examples include Npu DnaE, Cfa, Vma, and Ssp DnaE. 52
  • RNA binding proteins examples include MS2, Com, and PP7.
  • Examples of synthetic DNA-binding zinc fingers included here are ZF6/10, ZF8/7, ZF9, MK10, Zinc Finger 268, and Zinc Finger 268/NRE. 66,67
  • proteins that multimerize as a result of quaternary structure included here are E. coli ferritin, and the other chimeric forms of ferritin. 68,69
  • optogenetic “light-inducible proteins” examples include Cry2, CIBN, and Lov2-Ja. 61
  • peptides the enhance transduction included here are L17E, 70 Vectofusin-1 (Miltenyi Biotec), KALA, 71 and the various forms of nisin. 72
  • T1-T4 heVLPs that are produced and isolated can be loaded with biomolecule or chemical molecule cargo by utilizing nucleofection, lipid, polymer, or CaCl 2 transfection, sonication, freeze thaw, incubation at various temperatures, and/or heat shock of purified particles mixed with cargo. These techniques are adapted from techniques employed to load cargo into exosomes for therapeutic or research applications.
  • 100 ug of heVLPs can be resuspended in 200-450 ul of 50 mM trehalose in PBS, mixed with cargo at a desired concentration, and electroporated (GenePulser II Electroporation System with capacitance extender, Bio-Rad, Hercules, Calif., USA) in a 0.4 cm cuvette at 0.200 kV and 125 uF.
  • electroporated GenePulser II Electroporation System with capacitance extender, Bio-Rad, Hercules, Calif., USA
  • heVLPs are harvested from cell culture medium supernatant 36-48 hours post-transfection, or when heVLPs are at the maximum concentration in the medium of the producer cells (the producer cells are expelling particles into the media and at some point in time, the particle concentration in the media will be optimal for harvesting the particles).
  • Supernatant can be purified by any known methods in the art, such as centrifugation, ultracentrifugation, precipitation, ultrafiltration, and/or chromatography.
  • the supernatant is first filtered, e.g., to remove particles larger than 1 ⁇ m, e.g., through 0.45 pore size polyvinylidene fluoride hydrophilic membrane (Millipore Millex-HV) or 0.8 ⁇ m pore size mixed cellulose esters hydrophilic membrane (Millipore Millex-AA).
  • the supernatant can be further purified and concentrated, e.g., using ultracentrifugation, e.g., at a speed of 80,000 to 100,000 ⁇ g at a temperature between 1° C. and 5° C. for 1 to 2 hours, or at a speed of 8,000 to 15,000 g at a temperature between 1° C. and 5° C.
  • heVLPs are concentrated in the form of a centrifugate (pellet), which can be resuspended to a desired concentration, mixed with transduction-enhancing reagents, subjected to a buffer exchange, or used as is.
  • heVLP-containing supernatant can be filtered, precipitated, centrifuged and resuspended to a concentrated solution.
  • PEG polyethylene glycol
  • Purified particles are stable and can be stored at 4° C. for up to a week or ⁇ 80° C. for years without losing appreciable activity.
  • heVLPs are resuspended or undergo buffer exchange so that particles are suspended in an appropriate carrier.
  • buffer exchange can be performed by ultrafiltration (Sartorius Vivaspin 500 MWCO 100,000).
  • An exemplary appropriate carrier for heVLPs to be used for in vitro applications would preferably be a cell culture medium that is suitable for the cells that are to be transduced by heVLPs.
  • Transduction-enhancing reagents that can be mixed into the purified and concentrated heVLP solution for in vitro applications include reagents known by those familiar with the art (Miltenyl Biotec Vectofusin-1, Millipore Polybrene, Takara Retronectin, Sigma Protamine Sulfate, and the like).
  • transduction efficiency can be further increased by centrifugation.
  • the plate containing heVLPs applied to cells can be centrifuged at a speed of 1,150 g at room temperature for 30 minutes. After centrifugation, cells are returned into the appropriate cell culture incubator (humidified incubator at 37° C. with 5% CO 2 ).
  • An appropriate carrier for heVLPs to be administered to a mammal, especially a human would preferably be a pharmaceutically acceptable composition.
  • a “pharmaceutically acceptable composition” refers to a non-toxic semisolid, liquid, or aerosolized filler, diluent, encapsulating material, colloidal suspension or formulation auxiliary of any type. Preferably, this composition is suitable for injection. These may be in particular isotonic, sterile, saline solutions (monosodium or disodium phosphate, sodium, potassium, calcium or magnesium chloride and similar solutions or mixtures of such salts), or dry, especially freeze-dried compositions which upon addition, depending on the case, of sterilized water or physiological saline, permit the constitution of injectable solutions.
  • Another appropriate pharmaceutical form would be aerosolized particles for administration by intranasal inhalation or intratracheal intubation.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or suspensions.
  • the solution or suspension may comprise additives which are compatible with heVLPs and do not prevent heVLP entry into target cells.
  • the form must be sterile and must be fluid to the extent that the form can be administered with a syringe. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • An example of an appropriate solution is a buffer, such as phosphate buffered saline.
  • solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
  • the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • compositions comprising cargo-loaded heVLPs can be included in a container, pack, or dispenser together with instructions for administration.
  • PEI polyethylenimine
  • PEI MAX Polyethylenimine 25 kD linear
  • HEK293T cells were split to reach a confluency of 70%-90% at time of transfection and are cultured in 10% FBS DMEM media.
  • Cargo vectors such as one encoding a CMV promoter driving expression of a hPLC ⁇ 1 PH fusion to codon optimized Cas9 were co-transfected with a U6 promoter-sgRNA encoding plasmid, a hERVK con GAG (hGAGK con ) encoding plasmid, and a hENVW (Syncytin-1) encoding plasmid. Transfection reactions were assembled in reduced serum media (Opti-MEM; GIBCO #31985-070).
  • HEK293T cells For heVLP particle production on 10 cm plates, 5 ⁇ g PH-Cas9 expressing plasmid, 5 ⁇ g sgRNA-expression plasmid, 5 ⁇ g hERVK con GAG expression plasmid, and 5 ⁇ g Syncytin-1 expression plasmid were mixed in 1 mL Opti-MEM, followed by addition of 27.5 ⁇ l PEI MAX. After 20-30 min incubation at room temperature, the transfection reactions were dispersed dropwise over the HEK293T cells.
  • heVLPs were harvested at 48-72 hours post-transfection. heVLP supernatants were filtered using 0.8 ⁇ m pore size mixed cellulose esters membrane filters and transferred to polypropylene Beckman ultracentrifuge tubes that are used with the SW28 rotor (Beckman Coulter #326823). Each ultracentrifuge tube is filled with heVLP-containing supernatant from 3 10 cm plates to reach an approximate final volume of 35-37.5 ml. heVLP supernatant underwent ultracentrifugation at approximately 100,000 ⁇ g, or 25,000 rpm, at 4° C. for 2 hours.
  • heVLPs were added dropwise to cells that were seeded in a 24-well plate 24 hours prior to transduction.
  • Polybrene (5-10 ⁇ g/mL in cell culture medium; Sigma-Aldrich #TR-1003-G) was supplemented to enhance transduction efficiency, if necessary.
  • Vectofusin-1 (10 ⁇ g/mL in cell culture medium, Miltenyi Biotec #130-111-163) was supplemented to enhance transduction efficiency, if necessary.
  • the 24-well plate was centrifuged at 1,150 ⁇ g for 30 min at room temperature to enhance transduction efficiency, if necessary.
  • HEK 293T cells were transduced with T1heVLPs containing PLC PH fused to spCas9, hGAGK con fused to spCas9, or hArc fused to spCas9 targeted to VEGF site #3.
  • T1heVLPs were pseudotyped with either hENVW (left chart) or hENVFRD (right chart).
  • Gene modification was measured by amplicon sequencing.
  • Particle purification and concentration was performed by PVDF filtration and ultracentrifugation at 100,000 ⁇ g for 2 hours. Results are shown in FIG. 3 .
  • HERV-derived GAG hGAGK con
  • efficient delivery was not achieved.
  • hENVK4 envK4/K109 AF164615.1 6412-8508 (+) 8.
  • hENVK6 envK6/K115 AY037929.1 6442-8541 (+) 10.
  • hENVT envT AC078899.1 154738-156618 (+) 11.
  • ENV sequences used to derive this consensus ENV sequence are from the following HERVs: HERV-K113, HERV-K101, HERV-K102, HERV-K104, HERV-K107, HERV-K108, HERV-K109, HERV-K115, HERV- K11p22, and HERV-K12q13.
  • Epigenetic modulator Epigenetic modulation VP16 transcriptional activation VP64 transcriptional activation P65 transcriptional activation RTA transcriptional activation KRAB transcriptional repression MeCP2 transcriptional repression Tet1 Methylation Dnmt3a Methylation
  • Plasma membrane recruitment domains described in this work are TABLE 6 Plasma membrane recruitment domains described in this work. # Plasma membrane recruitment domain Substitution(s) 1. Pleckstrin homology domain of human phospholipase C ⁇ 1 (hPLC ⁇ 1) 2. Pleckstrin homology domain of human Akt1 3. Mutant Pleckstrin homology domain of E17K human Akt1 4. hArc *5. hGAGK con 6. Pleckstrin homology domain of human 3- phosphoinositide-dependent protein kinase 1 (hPDPK1) 7. Human CD9 8. Human CD47 9. Human CD63 10. Human CD81 *hGAGK con is a consensus sequence derived from ten proviral GAG sequences.
  • the GAG sequences used to derive this consensus GAG sequence are from the following HERVs: HERV-K113, HERV-K101, HERV-K102, HERV-K104, HERV-K107, HERV-K108, HERV-K109, HERV-K115, HERV- K11p22, and HERV-K12q13.
  • Homo sapiens Arc (SEQ ID NO: 1) MELDHRTSGGLHAYPGPRGGQVAKPNVILQIGKCRAEMLEHVRRTHRHLLAEVSKQVERELKGLHRSVGKLE SNLDGYVPTSDSQRWKKSIKACLCRCQETIANLERWVKREMHVVVREVFYRLERWADRLESTGGKYPVGSES ARHTVSVGVGGPESYCHEADGYDYTVSPYAITPPPAAGELPGQEPAEAQQYQPWVPGEDGQPSPGVDTQIFE DPREFLSHLEEYLRQVGGSEEYWLSQIQNHMNGPAKKVWVEFKQGSVKVWVEFKKEFLQYSEGTLSREAIQR ELDLPQKQGEPLDQFLWRKRDLYQTLYVDADEEEIIQYVVGTLQPKLKRFLRHPLPKTLEQLIQRGMEVQDD LEQAAEPAGPHLPVEDEAETLTPAP
  • PCC 6803 Ssp DnaE N-terminal Split Intein (SEQ ID NO: 50) CLSFGTEILTVEYGPLPIGKIVSEEINCSVYSVDPEGRVYTQAIAQWHDRGEQEVLEYELEDGSVIRATSDH RFLTTDYQLLAIEEIFARQLDLLTLENIKQTEEALDNHRLPFPLLDAGTIK Synechocystis sp.
  • PCC 6803 Ssp DnaE C-terminal Split Intein (SEQ ID NO: 51) MVKVIGRRSLGVQRIFDIGLPQDHNFLLANGAIAAN Synthetic: Spy Tag (SEQ ID NO: 52) VPTIVMVDAYKRYK Synthetic: Spy Catcher (SEQ ID NO: 53) MVTTLSGLSGEQGPSGDMTTEEDSATHIKFSKRDEDGRELAGATMELRDSSGKTISTWISDGHVKDFYLYPG KYTFVETAAPDGYEVATAITFTVNEQGQVTVNGEATKGDAHTGSSGS Bacteriophage A452: MS2 RNA Binding Protein (SEQ ID NO: 54) MASNFTQFVLVDNGGTGDVTVAPSNFANGVAEWISSNSRSQAYKVTCSVRQSSAQNRKYTIKVEVPKVATQT VGGVELPVAAWRSYLNMELTIPIFATNSDCELIVKAMQGLLKDGNPIPSAIAANSGIY Bacteriophage A
  • lactis F10 Nisin F (SEQ ID NO: 79) ITSISLCTPGCKTGALMGCNMKTATCNCSVHVSK Lactococcus lactis 61-14: Nisin Q (SEQ ID NO: 80) ITSISLCTPGCKTGVLMGCNLKTATCNCSVHVSK Streptococcus hyointestinalis : Nisin H (SEQ ID NO: 81) FTSISMCTPGCKTGALMTCNYKTATCHCSIKVSK Streptococcus uberis : Nisin U (SEQ ID NO: 82) ITSKSLCTPGCKTGILMTCPLKTATCGCHFG Streptococcus uberis : Nisin U2 (SEQ ID NO: 83) VTSKSLCTPGCKTGILMTCPLKTATCGCHFG Streptococcus galloyticus subsp.
  • lactis NZ9800 Nisin A S29A (SEQ ID NO: 85) ITSISLCTPGCKTGALMGCNMKTATCHCAIHVSK L. lactis NZ9800: Nisin A S29D (SEQ ID NO: 86) ITSISLCTPGCKTGALMGCNMKTATCHCDIHVSK L. lactis NZ9800: Nisin A S29E (SEQ ID NO: 87) ITSISLCTPGCKTGALMGCNMKTATCHCEIHVSK L.
  • lactis NZ9800 Nisin A S29G (SEQ ID NO: 88) ITSISLCTPGCKTGALMGCNMKTATCHCGIHVSK L. lactis NZ9800: Nisin A K22T (SEQ ID NO: 89) ITSISLCTPGCKTGALMGCNMTTATCHCSIHVSK L. lactis NZ9800: Nisin A N20P (SEQ ID NO: 90) ITSISLCTPGCKTGALMGCPMKTATCHCSIHVSK L. lactis NZ9800: Nisin A M21V (SEQ ID NO: 91) ITSISLCTPGCKTGALMGCNVKTATCHCSIHVSK L.
  • lactis NZ9800 Nisin A K22S (SEQ ID NO: 92) ITSISLCTPGCKTGALMGCNMSTATCHCSIHVSK L.
  • lactis NZ9800 Nisin Z N20K (SEQ ID NO: 93) ITSISLCTPGCKTGALMGCKMKTATCNCSIHVSK L.
  • lactis NZ9800 Nisin Z M21K (SEQ ID NO: 94) ITSISLCTPGCKTGALMGCNKKTATCNCSIHVSK AAV2: REP52 (SEQ ID NO: 95) MELVGWLVDKGITSEKQW1QEDQASYISFNAASNSRSQIKAALDNAGKIMSLTKTAPDYLVGQPVEDISSN RIYKILELNGYDPQYAASVFLGWATKKFGKRNTIWLFGPATTGKTNIAEAIAHTVPFYGCVNVVTNENFPFN DCVDKMVIVWVEEGKMTAKVVESAKAILGGSKVRVDQKCKSSAQIDPTPVIVTSNTNMCAVIDGNSTTFEHQ QPLQDRMFKFELTRRLDHDFGKVTKQEVKDFFRWAKDHVVEVEHEFYVKKGGAKKRPAPSDADISEPKRVRE SVAQPSTSDAEASINYADRYQNKCSRHVGMNLMLFPCRQCERMNQNSNIC

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
US17/617,490 2019-06-13 2020-06-15 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells Abandoned US20220259617A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/617,490 US20220259617A1 (en) 2019-06-13 2020-06-15 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861186P 2019-06-13 2019-06-13
PCT/US2020/037740 WO2020252455A1 (en) 2019-06-13 2020-06-15 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US17/617,490 US20220259617A1 (en) 2019-06-13 2020-06-15 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/037740 A-371-Of-International WO2020252455A1 (en) 2019-06-13 2020-06-15 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US18/351,689 Continuation US12351815B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US18/351,674 Continuation US12351814B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US18/351,800 Continuation US12404525B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells

Publications (1)

Publication Number Publication Date
US20220259617A1 true US20220259617A1 (en) 2022-08-18

Family

ID=73782119

Family Applications (4)

Application Number Title Priority Date Filing Date
US17/617,490 Abandoned US20220259617A1 (en) 2019-06-13 2020-06-15 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US18/351,674 Active US12351814B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US18/351,689 Active US12351815B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US18/351,800 Active US12404525B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells

Family Applications After (3)

Application Number Title Priority Date Filing Date
US18/351,674 Active US12351814B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US18/351,689 Active US12351815B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US18/351,800 Active US12404525B2 (en) 2019-06-13 2023-07-13 Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells

Country Status (6)

Country Link
US (4) US20220259617A1 (cg-RX-API-DMAC7.html)
EP (1) EP3982989A4 (cg-RX-API-DMAC7.html)
JP (1) JP7808292B2 (cg-RX-API-DMAC7.html)
CN (1) CN114258398A (cg-RX-API-DMAC7.html)
CA (1) CA3143327A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020252455A1 (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024108001A3 (en) * 2022-11-16 2024-07-04 The General Hospital Corporation Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules
WO2024129976A3 (en) * 2022-12-14 2024-10-17 Scribe Therapeutics Inc. Particle delivery systems
WO2024254518A3 (en) * 2023-06-07 2025-03-06 Nvelop Therapeutics, Inc. Compositions of lipid delivery particles and method of use thereof
US12319938B2 (en) 2020-07-24 2025-06-03 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2025135671A1 (ko) * 2023-12-20 2025-06-26 성균관대학교산학협력단 Oct4, sox2, klf4 단백질을 포함하는 엔지니어링된 바이러스-유사 입자를 유효성분으로 포함하는 노화의 예방 또는 치료용 약제학적 조성물
US12351815B2 (en) 2019-06-13 2025-07-08 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392674B2 (en) 2015-07-22 2019-08-27 President And Fellows Of Harvard College Evolution of site-specific recombinases
US12060553B2 (en) 2017-08-25 2024-08-13 President And Fellows Of Harvard College Evolution of BoNT peptidases
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
US12655182B2 (en) 2019-07-15 2026-06-16 President And Fellows Of Harvard College Evolved botulinum neurotoxins and uses thereof
WO2022133266A1 (en) * 2020-12-18 2022-06-23 The Broad Institute, Inc. Evolution of botulinum neurotoxin proteases
EP4284813A4 (en) * 2021-01-27 2025-03-12 Aera Therapeutics, Inc. Pnma2-based capsids and uses thereof
CN113337506B (zh) * 2021-06-21 2023-01-03 珠海乐维再生医学科技有限公司 CRISPRi介导的抑制瘢痕形成的外泌体及其制备方法和应用
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
GB202118946D0 (en) 2021-12-23 2022-02-09 Evox Therapeutics Ltd Engineered extracellular vesicles with improved cargo delivery
JP2025519070A (ja) 2022-05-17 2025-06-24 エンヴェロップ セラピューティクス， インコーポレイテッド 効率的ｉｎ ｖｉｖｏ送達のための組成物および方法
WO2024212185A1 (zh) * 2023-04-13 2024-10-17 清华大学 高效可控rna递送系统
WO2024218400A1 (en) * 2023-04-21 2024-10-24 Inprother Aps Improved expression of surface-displayed antigens
WO2025250903A1 (en) * 2024-05-31 2025-12-04 California Institute Of Technology Engineered enveloped nanoparticles (enps) as a delivery system for nucleic acid-based cargoes
CN120137909A (zh) * 2025-03-12 2025-06-13 广州酷奇圈科研与推广应用有限公司 重组外泌体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256046A1 (en) * 2012-12-12 2014-09-11 Massachusetts Institute Of Technology Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
WO2015191911A2 (en) * 2014-06-12 2015-12-17 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same
US20170065588A1 (en) * 2011-04-01 2017-03-09 Genentech, Inc. Biomarkers for predicting sensitivity to cancer treatments

Family Cites Families (370)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US5109113A (en) 1986-05-02 1992-04-28 Genentech, Inc. Membrane anchor fusion polypeptides
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5244797B1 (en) 1988-01-13 1998-08-25 Life Technologies Inc Cloned genes encoding reverse transcriptase lacking rnase h activity
US5223394A (en) 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2117477C (en) 1992-12-11 2001-06-12 Peter S. Mezes Multivalent single chain antibodies
GB9304239D0 (en) * 1993-03-01 1993-04-21 British Bio Technology Viral particles
BR9400600A (pt) 1994-02-17 1995-10-24 Finep Financiadora De Estudos Processos para produção de uma protéina recombinante e/ou de glicosilfosfatidilinositol (GPI) em células de microorganismos eucariontes e para a obtenção de leveduras de S. cerevisae; célula de levedura sequência de nucleotídios; meio de cultura; medicamento ou vacina; e produto dos ditos processos
WO1995031183A1 (en) 1994-05-16 1995-11-23 Washington University Cell membrane fusion composition and method
AU737727B2 (en) 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
AU7567298A (en) * 1997-05-09 1998-11-27 Fred Hutchinson Cancer Research Center (mus dunni) endogenous retroviral packaging cell lines
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US7994295B2 (en) 1997-12-22 2011-08-09 The University Of Tennessee Research Corporation Recombinant viruses comprising the membrane-proximal domain of VSV G protein
DE69942334D1 (de) 1998-03-02 2010-06-17 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
FR2780069B1 (fr) 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
DE69940521D1 (de) 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US7030215B2 (en) 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
GB9918680D0 (en) 1999-08-09 1999-10-13 Medical Res Council Polypeptide
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
JP2003514564A (ja) 1999-11-24 2003-04-22 エムシーエス マイクロ キャリア システムズ ゲーエムベーハー 核局在化シグナルまたはタンパク質導入領域の多量体を含むポリペプチド、および分子を細胞内へ移入するためのその使用法
CA2413995C (en) 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
ATE376059T1 (de) 2000-06-23 2007-11-15 Wyeth Corp Assemblierung von wildtyp und chimären influenzavirus-ähnlichen partikeln (vlps)
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US6395523B1 (en) 2001-06-01 2002-05-28 New England Biolabs, Inc. Engineering nicking endonucleases from type IIs restriction endonucleases
US7008669B2 (en) 2001-06-13 2006-03-07 Seiko Epson Corporation Ceramic and method of manufacturing the same, dielectric capacitor, semiconductor device, and element
US20040028687A1 (en) 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
WO2003082200A2 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
US9045727B2 (en) 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
EA008497B1 (ru) 2002-11-21 2007-06-29 Певион Биотех Лтд. Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
EP1651667B1 (en) 2003-04-04 2012-03-28 Centre National De La Recherche Scientifique Protein with fusogenic activity, nucleic acid sequences encoding said protein and pharmaceutical compositions comprising the same
US7011966B2 (en) 2003-04-16 2006-03-14 New England Biolabs, Inc. Method for cloning and expression of AcuI restriction endonuclease and AcuI methylase in E. coli
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
EP1709194A4 (en) 2003-12-17 2007-07-25 Univ Columbia DISTRIBUTION OF DNA OR RNA VIA NEXI OF HOST CELLS TO TARGET CELLS AND A CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR SIRNA
US7964196B2 (en) 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2006027202A1 (en) 2004-09-06 2006-03-16 Unite De Recherche En Biotherapie Et Oncologie (Rubio) Generation of multiparent cell hybrids
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
US7998733B2 (en) 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
GB0426641D0 (en) 2004-12-03 2005-01-05 Bioactive Protein Delivery The Protein delivery system
US9034650B2 (en) 2005-02-02 2015-05-19 Intrexon Corporation Site-specific serine recombinases and methods of their use
US8178291B2 (en) 2005-02-18 2012-05-15 Monogram Biosciences, Inc. Methods and compositions for determining hypersusceptibility of HIV-1 to non-nucleoside reverse transcriptase inhibitors
ATE466933T1 (de) 2005-03-15 2010-05-15 Cellectis I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung
CA2501301A1 (en) 2005-03-18 2006-09-18 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Human endogenous foamy retrovirus and uses thereof
EP2963118B1 (en) 2005-06-01 2017-08-09 California Institute of Technology Method of targeted gene delivery using viral vectors
EP1913149A4 (en) 2005-07-26 2009-08-05 Sangamo Biosciences Inc TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES
US9783791B2 (en) 2005-08-10 2017-10-10 Agilent Technologies, Inc. Mutant reverse transcriptase and methods of use
JP4938263B2 (ja) 2005-08-19 2012-05-23 独立行政法人農業生物資源研究所 一本鎖抗体によるサイトゾルタンパク質の機能阻害法およびその利用
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
WO2007099387A1 (en) 2006-03-03 2007-09-07 Mymetics Corporation Virosome-like vesicles comprising gp41-derived antigens
WO2007107156A2 (en) 2006-03-17 2007-09-27 Aarhus Universitet Chimeric viral envelopes
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CA2658393A1 (en) 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
AU2007291936B2 (en) 2006-08-30 2012-09-27 Artes Biotechnology Gmbh Recombinant proteins and virus like particles comprising L and S polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
ES2384006T3 (es) 2007-03-15 2012-06-28 Inserm Métodos para producir anticuerpos scFv activos y bibliotecas para los mismos
US20090226525A1 (en) 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
CN101668848B (zh) 2007-04-26 2014-10-22 雷蒙特亚特特拉维夫大学有限公司 来自口腔粘膜的多能自体干细胞和使用方法
US8703469B2 (en) 2007-07-06 2014-04-22 Boyce Thompson Institute For Plant Research Baculoviruses with enhanced virion production and a method for the production of baculoviruses
ES2708856T3 (es) 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales
EP2036980A1 (de) 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
AU2008305590A1 (en) 2007-09-27 2009-04-02 Sangamo Therapeutics, Inc. Genomic editing in zebrafish using zinc finger nucleases
ATE530169T1 (de) 2007-09-28 2011-11-15 Bind Biosciences Inc Krebszellen-targeting mit nanopartikeln
WO2009134866A2 (en) 2008-04-29 2009-11-05 The Brigham And Women's Hospital, Inc. Cell membrane engineering
CA2725773C (en) 2008-05-28 2017-12-05 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
US9296790B2 (en) 2008-10-03 2016-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for protein delivery
DE102008050860A1 (de) 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
EP2371376B1 (en) 2008-12-03 2014-04-16 Shanghai Institutes for Biological Sciences, CAS Methods and reagents for the diagnosis, prevention and treatment of insulin resistance
WO2010079208A1 (en) 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest
EP2398496B1 (en) 2009-02-20 2015-08-05 International AIDS Vaccine Initiative Vesicular stomatitis virus vectors encoding hiv env epitopes
JP5882064B2 (ja) 2009-03-04 2016-03-09 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 安定化された逆転写酵素融合タンパク質
CN102438658A (zh) 2009-03-13 2012-05-02 莱蒂恩公司 非整合型逆转录病毒载体疫苗
PT2419144T (pt) 2009-04-17 2019-09-16 Univ Oxford Innovation Ltd Composição para a administração de material genético
JP5667180B2 (ja) 2009-07-01 2015-02-12 イオン メディックス インコーポレイテッド 哺乳類の有核細胞に由来するマイクロベシクル及びその用途
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
WO2011058052A1 (en) 2009-11-13 2011-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Direct protein delivery with engineered microvesicles
EP2325322A1 (en) 2009-11-23 2011-05-25 4-Antibody AG Retroviral vector particles and methods for their generation and use
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
WO2011106376A2 (en) 2010-02-23 2011-09-01 The General Hospital Corporation Use of microvesicles in the treatment of medical conditions
US20130017210A1 (en) 2010-03-17 2013-01-17 Stc.Unm Display of antibody fragments on virus-like particles of rna bacteriophages
US20110311587A1 (en) 2010-06-04 2011-12-22 Pramila Walpita Fusogenic virus-like particles and uses thereof
WO2011159951A2 (en) 2010-06-17 2011-12-22 Sanford-Burnham Medical Research Institute Targeting tumor associated macrophages using bisphosphonate-loaded particles
WO2012054727A1 (en) 2010-10-22 2012-04-26 Bio-Rad Laboratories, Inc. Reverse transcriptase mixtures with improved storage stability
WO2012130336A1 (en) 2011-03-29 2012-10-04 Principium Europe S.R.L. Delivery of large molecular weight biologically active substances
WO2012168307A2 (en) 2011-06-07 2012-12-13 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Improved recombination efficiency by inhibition of nhej dna repair
EP2726494B1 (en) 2011-06-28 2017-01-04 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
JP2014525754A (ja) 2011-08-12 2014-10-02 バイレクシス コーポレイション アポトーシスを誘導するための組成物および方法
JP6177780B2 (ja) 2011-09-28 2017-08-09 エラ、ビオテック、ソシエダッド、アノニマＥｒａ Ｂｉｏｔｅｃｈ， Ｓ．Ａ． スプリットインテインおよびその使用
US9249426B2 (en) 2011-09-29 2016-02-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vectors pseudotyped with mutant BaEV glycoproteins
EP2583974B1 (en) 2011-10-21 2017-04-26 Technische Universität Dresden Pseudotyping of foamy viruses
JP6232544B2 (ja) 2011-11-11 2017-11-22 ヴァリエーション バイオテクノロジーズ インコーポレイテッド サイトメガロウイルスの治療のための組成物及び方法
WO2013074999A1 (en) 2011-11-16 2013-05-23 Sangamo Biosciences, Inc. Modified dna-binding proteins and uses thereof
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
WO2013098813A1 (en) 2012-01-01 2013-07-04 Qbi Enterprises Ltd. Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
US9528107B2 (en) 2012-01-31 2016-12-27 Pacific Biosciences Of California, Inc. Compositions and methods for selection of nucleic acids
US9737480B2 (en) 2012-02-06 2017-08-22 President And Fellows Of Harvard College ARRDC1-mediated microvesicles (ARMMs) and uses thereof
EP2636746A1 (en) 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9610346B2 (en) 2012-03-23 2017-04-04 International Aids Vaccine Initiative Recombinant viral vectors
JP2015527296A (ja) 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたｒｎａの新規の送達
WO2013148327A1 (en) 2012-03-26 2013-10-03 The Regents Of The University Of California Nipah virus envelope psuedotyped lentiviruses and methods of their use
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
PT2877490T (pt) 2012-06-27 2019-02-12 Univ Princeton Inteínas clivadas, conjugados e suas utilizações
US9994829B2 (en) 2012-07-02 2018-06-12 Iprogen Biotech, Inc. Intracellular protein delivery
US9181535B2 (en) 2012-09-24 2015-11-10 The Chinese University Of Hong Kong Transcription activator-like effector nucleases (TALENs)
US10047352B2 (en) 2012-10-03 2018-08-14 Agrivida, Inc. Intein-modified proteases, their production and industrial applications
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
EP3269388A1 (en) 2012-10-30 2018-01-17 Pfizer Inc. Recombinant particle based vaccines against human cytomegalovirus infection
BR112015012811A2 (pt) 2012-12-06 2017-11-14 Exxonmobil Res & Eng Co genes dgat compreendendo domínios de homologia de plecstrina e uso em micro-organismos recombinantes
EP3064585B1 (en) 2012-12-12 2020-02-05 The Broad Institute, Inc. Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US9504747B2 (en) 2013-03-08 2016-11-29 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP2983721B2 (en) 2013-04-12 2021-01-20 Evox Therapeutics Limited Therapeutic delivery vesicles
CA3166758A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
CN105283553B (zh) 2013-06-11 2021-06-25 克隆技术实验室有限公司 蛋白质富集的微泡及其制备和使用方法
JP6738728B2 (ja) 2013-06-17 2020-08-19 ザ・ブロード・インスティテュート・インコーポレイテッド 肝臓ターゲティングおよび治療のためのＣＲＩＳＰＲ−Ｃａｓ系、ベクターおよび組成物の送達および使用
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US20160208221A1 (en) 2013-09-12 2016-07-21 Apse, Llc Compositions and methods using capsids resistant to hydrolases
WO2015048566A1 (en) 2013-09-26 2015-04-02 The General Hospital Corporation Methods of isolating extracellular vesicles
US10538570B2 (en) 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
CN111206032B (zh) 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
JP6412579B2 (ja) 2014-01-10 2018-10-24 シリオン・バイオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 偽型レンチウイルスベクター
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
WO2015138878A1 (en) 2014-03-13 2015-09-17 Research Institute At Nationwide Children's Hospital, Inc. Methods of delivering heparin binding epidermal growth factor using stem cell generated exosomes
US20160051697A1 (en) 2014-04-07 2016-02-25 The Board Of Regents For Oklahoma State University Nanodelivery device for therapeutic loading of circulating erythrocytes
KR20170068410A (ko) 2014-04-29 2017-06-19 내셔날 헬스 리서치 인스티튜트 엔테로바이러스 감염증에 대항하는 아데노바이러스 벡터-기반 백신
US20150344523A1 (en) 2014-05-05 2015-12-03 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
WO2015191693A2 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10583104B2 (en) 2014-08-06 2020-03-10 Indiana University Research And Technology Corporation Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
US10442863B2 (en) 2014-09-08 2019-10-15 Lutana Gmbh Construct for the delivery of a molecule into the cytoplasm of a cell
US10010607B2 (en) 2014-09-16 2018-07-03 Institut Curie Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response
EP3845655B1 (en) 2014-10-01 2025-01-01 The General Hospital Corporation Methods for increasing efficiency of nuclease-induced homology-directed repair
DK3212778T3 (da) 2014-10-28 2019-11-04 Agrivida Inc Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
CA2969619A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
HRP20240357T1 (hr) 2014-12-24 2024-06-07 Autolus Limited Stanica
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016149426A1 (en) 2015-03-16 2016-09-22 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
WO2016149384A1 (en) 2015-03-18 2016-09-22 University Of Massachusetts Virus-like particle compositions and vaccines against epstein-barr virus infection and disease
WO2016185125A1 (fr) 2015-05-15 2016-11-24 Vectalys Particule rétrovirale comportant au moins deux arn non viraux encapsidés
EA201890006A1 (ru) 2015-06-10 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Применение экзосом для лечения болезни
JP2018521689A (ja) 2015-06-17 2018-08-09 ポセイダ セラピューティクス， インコーポレイテッド タンパク質をゲノム内の特定の遺伝子座に導くための組成物および方法
US10624849B2 (en) 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites
WO2017059241A1 (en) 2015-10-02 2017-04-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral protein delivery system for rna-guided genome editing
JP7059179B2 (ja) 2015-10-20 2022-04-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 遺伝子操作のための方法及び製品
ES3036774T3 (en) 2015-10-20 2025-09-24 Inst Nat Sante Rech Med Methods and products for genetic engineering
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US20170112773A1 (en) 2015-10-23 2017-04-27 Board Of Regents, The University Of Texas System Plasma membrane vesicles comprising functional transmembrane proteins
US10316295B2 (en) * 2015-12-17 2019-06-11 The Penn State Research Foundation Paramyxovirus virus-like particles as protein delivery vehicles
EP3417062B1 (en) 2016-02-15 2024-06-26 Temple University - Of The Commonwealth System of Higher Education Excision of retroviral nucleic acid sequences
CN108698149B (zh) 2016-02-23 2020-03-03 弗罗纽斯国际有限公司 具有用于钎料的激光预热装置的焊接设备
SG10202008883SA (en) 2016-03-15 2020-10-29 Codiak Biosciences Inc Therapeutic membrane vesicles
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
EP3235828A1 (en) 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
JP6916209B2 (ja) 2016-05-13 2021-08-11 フラッシュ セラピューティクス 特に免疫応答に関与する細胞への、ｒｎａの転移のためのウイルス粒子
AU2017263137B2 (en) 2016-05-13 2021-05-27 Flash Therapeutics Particle for the encapsidation of a genome engineering system
GB201609216D0 (en) 2016-05-25 2016-07-06 Evox Therapeutics And Isis Innovation Ltd Exosomes comprising therapeutic polypeptides
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
GB201610041D0 (en) 2016-06-08 2016-07-20 Oxford Genetics Ltd Methods
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
AU2017283713B2 (en) 2016-06-17 2021-04-08 Massachusetts Institute Of Technology Type VI CRISPR orthologs and systems
GB2552460A (en) 2016-07-11 2018-01-31 Evox Therapeutics Ltd CPP-Mediated EV Loading
GB2552301A (en) 2016-07-11 2018-01-24 Evox Therapeutics Ltd Metabolic drug loading of EVs
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
EP3275462A1 (en) 2016-07-27 2018-01-31 Fundació Privada Institut de Recerca de la SIDA-Caixa Virus-like particles with high-density coating for the production of neutralizing antibodies
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
IL264439B2 (en) 2016-08-17 2024-08-01 Factor Bioscience Inc non-viral, cell-free composition comprising a synthetic messenger RNA (MRNA) encoding a gene-editing protein for use in treating cancer, and a synthetic RNA encoding a gene-editing protein for use in treatment
WO2018035387A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US11352647B2 (en) 2016-08-17 2022-06-07 The Broad Institute, Inc. Crispr enzymes and systems
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US9580698B1 (en) 2016-09-23 2017-02-28 New England Biolabs, Inc. Mutant reverse transcriptase
EP3518981A4 (en) 2016-10-03 2020-06-10 President and Fellows of Harvard College THERAPEUTIC RNA DELIVERY THROUGH ARRDC1 MICROVESICLES
WO2018083606A1 (en) 2016-11-01 2018-05-11 Novartis Ag Methods and compositions for enhancing gene editing
US11160823B2 (en) * 2016-11-07 2021-11-02 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
EP3540056A4 (en) 2016-11-10 2020-06-03 Kaneka Corporation METHOD FOR PRODUCING TRANSGENIC CELLS
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
US11192929B2 (en) 2016-12-08 2021-12-07 Regents Of The University Of Minnesota Site-specific DNA base editing using modified APOBEC enzymes
KR20190100174A (ko) 2016-12-23 2019-08-28 엑소팜 리미티드 미세소포 및 엑소좀의 정제 또는 단리를 위한 방법 및 조성물
GB201702863D0 (en) 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018191750A2 (en) 2017-04-14 2018-10-18 The Broad Institute Inc. Novel delivery of large payloads
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
CA3062614A1 (en) 2017-05-10 2018-11-15 University Of Utah Research Foundation Compositions and methods of use of arc capsids
CA3063733A1 (en) 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
WO2018226602A1 (en) 2017-06-05 2018-12-13 Research Institute At Nationwide Children's Hospital Enhanced modified viral capsid proteins
CA3066750A1 (en) 2017-06-13 2018-12-20 Flagship Pioneering Innovations V, Inc. Compositions comprising curons and uses thereof
EP3641804A1 (en) 2017-06-22 2020-04-29 Institut Gustave Roussy Human endogenous retroviral protein
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
AU2018316803B2 (en) 2017-08-17 2021-07-15 Ilias Biologics Inc. Exosomes for target specific delivery and methods for preparing and delivering the same
US11351247B2 (en) * 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
EP3688162B1 (en) 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
WO2019077150A1 (en) * 2017-10-20 2019-04-25 Genethon USE OF SYNCYTIN TO TARGET A MEDICINAL PRODUCT AND GENE ADMINISTRATION TO PULMONARY TISSUE
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
FR3072973B1 (fr) 2017-10-26 2022-02-11 Univ Pierre Et Marie Curie Paris 6 Particules pseudo-virales utiles pour traiter des dysfonctionnements immunitaires
CN117487776A (zh) 2017-11-01 2024-02-02 加利福尼亚大学董事会 Casz组合物和使用方法
WO2019089808A1 (en) 2017-11-01 2019-05-09 The Regents Of The University Of California Class 2 crispr/cas compositions and methods of use
EP3720502A4 (en) 2017-12-07 2022-01-19 Flagship Pioneering Innovations V, Inc. CYTOBIOLOGICS AND THERAPEUTIC USES THEREOF
US20210163933A1 (en) 2017-12-11 2021-06-03 University Of Massachusetts Arc protein extracellular vesicle nucleic acid delivery platform
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019126774A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Novel crispr enzymes and systems
GB201802163D0 (en) 2018-02-09 2018-03-28 Evox Therapeutics Ltd Compositions for EV storage and formulation
BR112020016570A2 (pt) 2018-02-17 2020-12-15 Flagship Pioneering Innovations V, Inc. Composições e métodos para liberação de proteína de membrana
GB201804291D0 (en) 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
WO2019199941A1 (en) 2018-04-10 2019-10-17 Northwestern University Extracellular vesicles comprising targeting affinity domain-based membrane proteins
WO2019213257A1 (en) 2018-05-01 2019-11-07 Wake Forest University Health Sciences Lentiviral-based vectors and related systems and methods for eukaryotic gene editing
KR102853088B1 (ko) 2018-05-11 2025-09-02 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법
KR102959497B1 (ko) 2018-05-11 2026-05-04 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법
CN112367973A (zh) * 2018-05-15 2021-02-12 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CA3105953A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
US20210261957A1 (en) 2018-07-10 2021-08-26 Alia Therapeutics S.R.L. Vesicles for traceless delivery of guide rna molecules and/or guide rna molecule/rna-guided nuclease complex(es) and a production method thereof
JP7306721B2 (ja) 2018-07-13 2023-07-11 国立大学法人京都大学 ウイルス様粒子及びその使用
WO2020027982A1 (en) 2018-08-02 2020-02-06 Editas Medicine, Inc. Compositions and methods for treating cep290-associated disease
KR102894715B1 (ko) 2018-08-03 2025-12-03 빔 테라퓨틱스, 인크. 핵산 표적 서열을 변형시키기 위한 다중-이펙터 핵염기 편집기 및 이를 이용하는 방법
WO2020041751A1 (en) 2018-08-23 2020-02-27 The Broad Institute, Inc. Cas9 variants having non-canonical pam specificities and uses thereof
AU2019327449B2 (en) 2018-08-28 2026-04-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
US20240173430A1 (en) 2018-09-05 2024-05-30 The Broad Institute, Inc. Base editing for treating hutchinson-gilford progeria syndrome
KR20210055733A (ko) 2018-09-07 2021-05-17 빔 테라퓨틱스, 인크. 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
US20220025397A1 (en) 2018-09-28 2022-01-27 The Regents Of The University Of California Ligand-directed targeting vectors
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
SG11202103756XA (en) 2018-10-19 2021-05-28 Ohio State Innovation Foundation Extracellular vesicles for targeted therapies against myeloid-derived suppressor cells
US20210363509A1 (en) 2018-10-22 2021-11-25 University Of Rochester Genome Editing by Directed Non-Homologous DNA Insertion Using a Retroviral Integrase-Cas9 Fusion Protein
WO2020086908A1 (en) 2018-10-24 2020-04-30 The Broad Institute, Inc. Constructs for improved hdr-dependent genomic editing
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
EP3880179A2 (en) 2018-11-14 2021-09-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
US20230048166A1 (en) 2018-11-14 2023-02-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
KR20210131991A (ko) 2018-11-14 2021-11-03 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 구획-특이적 카고 전달을 위한 조성물 및 방법
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
WO2020102659A1 (en) 2018-11-15 2020-05-22 The Broad Institute, Inc. G-to-t base editors and uses thereof
WO2020102709A1 (en) 2018-11-16 2020-05-22 The Regents Of The University Of California Compositions and methods for delivering crispr/cas effector polypeptides
JP7641005B2 (ja) 2018-12-27 2025-03-06 ヴェリミューン インコーポレイテッド コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
US20220194990A1 (en) 2019-01-31 2022-06-23 Board Of Regents Of The University Of Nebraska Virus-like particles and methods of use thereof
US20200248156A1 (en) 2019-02-01 2020-08-06 The General Hospital Corporation Targetable 3`-Overhang Nuclease Fusion Proteins
JP2022519275A (ja) 2019-02-04 2022-03-22 コディアック バイオサイエンシーズ， インコーポレイテッド エクソソーム操作のための膜タンパク質足場
US20220177877A1 (en) 2019-03-04 2022-06-09 President And Fellows Of Harvard College Highly multiplexed base editing
EP4219700A1 (en) 2019-03-07 2023-08-02 The Regents of the University of California Crispr-cas effector polypeptides and methods of use thereof
US20200347100A1 (en) 2019-03-15 2020-11-05 The Broad Institute, Inc. Non-naturally occurring capsids for delivery of nucleic acids and/or proteins
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3715453A1 (en) 2019-03-26 2020-09-30 Johann Wolfgang Goethe-Universität Frankfurt Methods and products for a safe and efficient transduction of gene editing components
EP3947687A1 (en) 2019-03-29 2022-02-09 Massachusetts Institute of Technology Constructs for continuous monitoring of live cells
WO2020210751A1 (en) 2019-04-12 2020-10-15 The Broad Institute, Inc. System for genome editing
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220184225A1 (en) 2019-04-23 2022-06-16 Case Western Reserve University Fusogenic particles and related methods for delivering therapeutic agents to cells
WO2020225287A1 (en) 2019-05-06 2020-11-12 Veterinärmedizinische Universität Wien Lentiviral nanoparticles
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
GB201910651D0 (en) 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle
US11401530B2 (en) 2019-08-19 2022-08-02 The Catholic University Of America Bacteriophage-based artificial viruses for human genome remodeling
CN119913134A (zh) 2019-08-29 2025-05-02 比姆医疗股份有限公司 用于编辑突变以允许转录或表达的组合物和方法
EP4025698A1 (en) 2019-09-03 2022-07-13 Sana Biotechnology, Inc. Cd24-associated particles and related methods and uses thereof
CA3153563A1 (en) 2019-09-09 2021-03-18 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
US12551560B2 (en) 2019-09-09 2026-02-17 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
US20230025039A1 (en) 2019-09-20 2023-01-26 The Broad Institute, Inc. Novel type vi crispr enzymes and systems
CN114616336B (zh) 2019-09-20 2025-11-14 博德研究所 用于将货物递送至靶细胞的组合物和方法
EP4034088A4 (en) 2019-09-26 2023-10-11 President and Fellows of Harvard College Minimal arrestin domain containing protein 1 (arrdc1) constructs
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
GB201915855D0 (en) 2019-10-31 2019-12-18 Univ Oxford Innovation Ltd An extracellular vesicle
WO2021091974A1 (en) 2019-11-08 2021-05-14 The Regents Of The University Of California Compositions and methods for temporal control of cell modulation
US20230040216A1 (en) 2019-11-19 2023-02-09 The Broad Institute, Inc. Retrotransposons and use thereof
WO2021108717A2 (en) 2019-11-26 2021-06-03 The Broad Institute, Inc Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
CA3162908A1 (en) 2019-12-03 2021-06-10 Beam Therapeutics Inc. Synthetic guide rna, compositions, methods, and uses thereof
WO2021113772A1 (en) 2019-12-06 2021-06-10 Scribe Therapeutics Inc. Particle delivery systems
EP4118098A4 (en) 2020-03-11 2024-06-12 The Trustees of The University of Pennsylvania METHOD AND COMPOSITION FOR GENE DELIVERY USING AN MANIPULATED VIRUS PARTICLE
AU2021236391A1 (en) 2020-03-13 2022-09-29 Capricor, Inc. Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms
WO2021184022A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Targeted delivery of extracellular vesicles
WO2021188761A1 (en) 2020-03-18 2021-09-23 University Of Florida Research Foundation, Incorporated Modified arrestin-1 to enhance photoreceptor survival in retinal disease
WO2021188840A1 (en) 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
US20230365989A1 (en) 2020-03-20 2023-11-16 The Broad Institute, Inc. Compositions and methods for enhanced lentiviral production
AU2021248815A1 (en) 2020-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Targeted lipid particles and compositions and uses thereof
JP2023515708A (ja) 2020-04-27 2023-04-13 アルナ バイオ， インコーポレーテッド 中枢神経系送達のための結合剤及びその使用
WO2021222318A1 (en) 2020-04-28 2021-11-04 The Broad Institute, Inc. Targeted base editing of the ush2a gene
CN116234902A (zh) 2020-05-04 2023-06-06 利兰·斯坦福青年大学托管委员会 用于激活和沉默基因表达的效应物结构域的生成、鉴定和表征的组合物、系统和方法
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
CN116234583A (zh) 2020-06-12 2023-06-06 哈佛大学的校长及成员们 Arrdc1介导的基于微泡的向神经系统的递送
JP2023531506A (ja) 2020-06-23 2023-07-24 ザ ジェネラル ホスピタル コーポレイション トンネルナノチューブ細胞および生体分子の送達のためのその使用方法
CN116157116A (zh) 2020-07-06 2023-05-23 旗舰先锋创新V股份有限公司 用于产生病毒融合体的方法和组合物
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
MX2023001164A (es) 2020-07-29 2023-09-15 Univ America Catholic Diseño de virus artificiales a base de bacteriofagos para la remodelación del genoma humano.
CA3193099A1 (en) 2020-09-24 2022-03-31 David R. Liu Prime editing guide rnas, compositions thereof, and methods of using the same
CA3094859A1 (en) 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
JP2023545831A (ja) 2020-10-16 2023-10-31 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｗｗドメイン活性化細胞外ベシクル
CA3195463A1 (en) 2020-10-16 2022-04-21 President And Fellows Of Harvard College Ww-domain-activated extracellular vesicles targeting coronaviruses
CN116601164A (zh) 2020-10-16 2023-08-15 哈佛大学的校长及成员们 靶向hiv的ww结构域激活的细胞外囊泡
KR20230091894A (ko) 2020-10-21 2023-06-23 메사추세츠 인스티튜트 오브 테크놀로지 부위 특이적 표적화 요소를 통한 프로그램 가능한 첨가(paste)를 사용하는 부위 특이적 유전 공학을 위한 시스템, 방법, 및 조성물
EP4240380A4 (en) 2020-11-04 2024-10-16 Senti Biosciences, Inc. PROTEIN PAYLOAD RELEASE
JP2023550381A (ja) 2020-11-19 2023-12-01 ウェイク・フォレスト・ユニバーシティ・ヘルス・サイエンシーズ 真核生物遺伝子編集のためのベクター、システムおよび方法
WO2022119957A1 (en) 2020-12-02 2022-06-09 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
WO2022133266A1 (en) 2020-12-18 2022-06-23 The Broad Institute, Inc. Evolution of botulinum neurotoxin proteases
KR20230151513A (ko) 2021-01-11 2023-11-01 사나 바이오테크놀로지, 인크. Cd8 표적 바이러스 벡터의 용도
EP4284813A4 (en) 2021-01-27 2025-03-12 Aera Therapeutics, Inc. Pnma2-based capsids and uses thereof
WO2022165262A1 (en) 2021-01-28 2022-08-04 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
US20240132916A1 (en) 2021-02-09 2024-04-25 The Broad Institute, Inc. Nuclease-guided non-ltr retrotransposons and uses thereof
WO2022192879A1 (en) 2021-03-09 2022-09-15 Florida State University Research Foundation, Inc. Lipid vesicle-mediated delivery to cells
JP2024532963A (ja) 2021-04-08 2024-09-11 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ８特異的抗体コンストラクト及びその組成物
CA3217115A1 (en) 2021-04-30 2022-11-03 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting lipid nanoparticle therapeutics to stem cells
US12565647B2 (en) 2021-05-28 2026-03-03 The Regents Of The University Of California Compositions and methods for targeted delivery of CRISPR-Cas effector polypeptides and transgenes
IL308836A (en) 2021-05-28 2024-01-01 Sana Biotechnology Inc Lipid Particles Containing Baboon Truncated Endogenous Retrovirus (BAEV) Envelope Glycoprotein and Related Methods and Uses
US20240207196A1 (en) 2021-06-09 2024-06-27 Scribe Therapeutics Inc. Compositions of glycoprotein particles
WO2022261150A2 (en) 2021-06-09 2022-12-15 Scribe Therapeutics Inc. Particle delivery systems
EP4381081A1 (en) 2021-08-04 2024-06-12 Sana Biotechnology, Inc. Use of cd4-targeted viral vectors
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
US20240417719A1 (en) 2021-10-25 2024-12-19 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
WO2023077107A1 (en) 2021-10-29 2023-05-04 Sana Biotechnology, Inc. Methods and reagents for amplifying viral vector nucleic acid products
EP4426828A1 (en) 2021-11-01 2024-09-11 Tome Biosciences, Inc. Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
IL313146A (en) 2021-12-03 2024-07-01 Harvard College Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
US20250223584A2 (en) 2021-12-03 2025-07-10 The Broad Institute, Inc. Compositions and methods for efficient in vivo delivery
AU2022400961A1 (en) 2021-12-03 2024-05-30 President And Fellows Of Harvard College Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same
EP4444744A4 (en) 2021-12-09 2025-11-26 Vesigen Inc ARRDC1-Mediated Microvesicle Degradation System (ARMM) and its Uses
WO2023114949A1 (en) 2021-12-16 2023-06-22 Sana Biotechnology, Inc. Methods and systems of particle production
EP4448775A1 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
US20250059239A1 (en) 2021-12-17 2025-02-20 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
US20250057980A1 (en) 2021-12-22 2025-02-20 Tome Biosciences, Inc. Co-Delivery of a Gene Editor Construct and a Donor Template
GB202118946D0 (en) 2021-12-23 2022-02-09 Evox Therapeutics Ltd Engineered extracellular vesicles with improved cargo delivery
EP4456902A4 (en) 2021-12-29 2025-12-31 Intima Bioscience Inc ANTIGEN DELIVERY PLATFORM AND METHODS OF USE
WO2023133422A1 (en) 2022-01-04 2023-07-13 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
WO2023133425A1 (en) 2022-01-04 2023-07-13 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
US20250177555A1 (en) 2022-03-09 2025-06-05 The Regents Of The University Of Colorado A Body Corporate Tissue and cell-type specific delivery of therapeutic molecules incorporating viral and human fusiogenic proteins
EP4493157A4 (en) 2022-03-11 2026-06-24 Harvard College TARGETED DISTRIBUTION OF ARMM
WO2023205744A1 (en) 2022-04-20 2023-10-26 Tome Biosciences, Inc. Programmable gene insertion compositions
EP4511486A1 (en) 2022-04-20 2025-02-26 Massachusetts Institute Of Technology Site specific genetic engineering utilizing trans-template rnas
WO2023205710A1 (en) 2022-04-20 2023-10-26 Massachusetts Institute Of Technology Programmable gene editing using guide rna pair
WO2023215831A1 (en) 2022-05-04 2023-11-09 Tome Biosciences, Inc. Guide rna compositions for programmable gene insertion
JP2025519070A (ja) 2022-05-17 2025-06-24 エンヴェロップ セラピューティクス， インコーポレイテッド 効率的ｉｎ ｖｉｖｏ送達のための組成物および方法
WO2023225670A2 (en) 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
US20230383288A1 (en) 2022-05-25 2023-11-30 Massachusetts Institute Of Technology Systems, methods, and compositions for rna-guided rna-targeting crispr effectors
WO2023230601A1 (en) 2022-05-27 2023-11-30 Beam Therapeutics Inc. Identification of nanoparticles for preferential tissue or cell targeting
WO2023240027A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Particle delivery systems
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
CA3259504A1 (en) 2022-06-15 2023-12-21 Vesigen, Inc. ARRDC1-mediated microvesicular administration of therapeutic agents to peripheral nervous system cells
WO2024006988A2 (en) 2022-06-30 2024-01-04 The Broad Institute, Inc. Engineered delivery vesicles and uses thereof
US20250302761A1 (en) 2022-07-21 2025-10-02 Institut National de la Santé et de la Recherche Médicale Extracellular vesicles functionalized with an erv syncitin and uses thereof for cargo delivery
GB202210861D0 (en) 2022-07-25 2022-09-07 Univ Oxford Innovation Ltd Loaded extracellular vesicle
WO2024026295A1 (en) 2022-07-27 2024-02-01 Aera Therapeutics, Inc. Endogenous gag-based and pnma family capsids and uses thereof
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
EP4580647A1 (en) 2022-08-31 2025-07-09 The Broad Institute, Inc. Gtp cyclohydrolase-cleaving proteases
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
US20240191256A1 (en) 2022-11-16 2024-06-13 The General Hospital Corporation Virus-like Particles with Programmable Tropism and Methods of Use Thereof for Delivery to Cells
WO2024107959A1 (en) 2022-11-16 2024-05-23 The General Hospital Corporation Minimal virus-like particles and methods of use thereof for delivery of biomolecules
WO2024108001A2 (en) 2022-11-16 2024-05-23 The General Hospital Corporation Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules
WO2024138033A2 (en) 2022-12-21 2024-06-27 Nvelop Therapeutics, Inc. Compositions and methods for delivery of nucleic acid editors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170065588A1 (en) * 2011-04-01 2017-03-09 Genentech, Inc. Biomarkers for predicting sensitivity to cancer treatments
US20140256046A1 (en) * 2012-12-12 2014-09-11 Massachusetts Institute Of Technology Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
WO2015191911A2 (en) * 2014-06-12 2015-12-17 Clontech Laboratories, Inc. Protein enriched microvesicles and methods of making and using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Banskota et al, Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins, 2022, Cell 185, 250–265` *
Raguram et al, Therapeutic in vivo delivery of gene editing agents, Cell. 2022 July 21; 185(15): 2806–2827 *
Song et al, 442. The Human Endogenous Retrovirus HERV-W Envelope Glycoprotein Forms Pseudotypes with HIV-1 Vectors, S144, Molecular Therapy Vol. 5, No. 5, May 2002 *
Tonjes et al, Characterization of Human Endogenous Retrovirus Type K Virus-like ParticlesGenerated from Recombinant Baculoviruses, Virology, 1997, pages 280-291 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12351815B2 (en) 2019-06-13 2025-07-08 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US12351814B2 (en) 2019-06-13 2025-07-08 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US12404525B2 (en) 2019-06-13 2025-09-02 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US12319938B2 (en) 2020-07-24 2025-06-03 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2024108001A3 (en) * 2022-11-16 2024-07-04 The General Hospital Corporation Minimal human-derived virus-like particles and methods of use thereof for delivery of biomolecules
WO2024129976A3 (en) * 2022-12-14 2024-10-17 Scribe Therapeutics Inc. Particle delivery systems
WO2024254518A3 (en) * 2023-06-07 2025-03-06 Nvelop Therapeutics, Inc. Compositions of lipid delivery particles and method of use thereof
WO2025135671A1 (ko) * 2023-12-20 2025-06-26 성균관대학교산학협력단 Oct4, sox2, klf4 단백질을 포함하는 엔지니어링된 바이러스-유사 입자를 유효성분으로 포함하는 노화의 예방 또는 치료용 약제학적 조성물

Also Published As

Publication number Publication date
US20240011049A1 (en) 2024-01-11
WO2020252455A1 (en) 2020-12-17
CN114258398A (zh) 2022-03-29
US12351815B2 (en) 2025-07-08
US12404525B2 (en) 2025-09-02
US20240011050A1 (en) 2024-01-11
JP2022536364A (ja) 2022-08-15
US20240018544A1 (en) 2024-01-18
US12351814B2 (en) 2025-07-08
EP3982989A1 (en) 2022-04-20
EP3982989A4 (en) 2023-07-19
JP7808292B2 (ja) 2026-01-29
CA3143327A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
US12404525B2 (en) Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
US12319938B2 (en) Enhanced virus-like particles and methods of use thereof for delivery to cells
Whitley et al. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing
Nowakowski et al. Genetic engineering of stem cells for enhanced therapy
US20240191256A1 (en) Virus-like Particles with Programmable Tropism and Methods of Use Thereof for Delivery to Cells
US20100233141A1 (en) Compositions And Methods For The Delivery Of Biologically Active RNAs
US20240189247A1 (en) Minimal Human-Derived Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules
US20240191208A1 (en) Minimal Virus-Like Particles and Methods of Use Thereof for Delivery of Biomolecules
JP2024003220A (ja) 修飾型閉端ｄｎａ（ｃｅｄｎａ）を使用する遺伝子編集
AU2012358181A1 (en) Compositions and methods for the delivery of biologically active RNAs
US20220002718A1 (en) Tunneling nanotube cells and methods of use thereof for delivery of biomolecules
HK40093951A (en) Enhanced virus-like particles and methods of use thereof for delivery to cells
Khoshaman et al. New frontiers in CRISPR/Cas9 delivery systems delivery for gene editing
WO2024229254A2 (en) Cellular delivery of therapeutics using fusogenic vesicles
Khalil et al. Literature Review: Historical and Current Developments in Gene Delivery Technologies Relevant to Therapeutic Use

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOUNG, J. KEITH;CABECEIRAS, PETER;SIGNING DATES FROM 20220211 TO 20220627;REEL/FRAME:060739/0169

AS Assignment

Owner name: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE GENERAL HOSPITAL CORPORATION;REEL/FRAME:062069/0051

Effective date: 20221201

Owner name: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE GENERAL HOSPITAL CORPORATION;REEL/FRAME:062069/0051

Effective date: 20221201

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION COUNTED, NOT YET MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION